Multimethodological study of molecular recognition phenomena by Fortugno, Cecilia
Alma Mater Studiorum – Università di Bologna 
in cotutela con Università di Ginevra 
 
 
DOTTORATO DI RICERCA IN 
 
CHIMICA 
 
 Ciclo XXVI  
 
Settore Concorsuale di afferenza: 03/D1 
 
Settore Scientifico disciplinare: CHIM/08 
 
 
 
 
Multimethodological study of molecular recognition phenomena 
 
 
 
 
 
Presentata da: Cecilia Fortugno 
 
 
 
Coordinatore Dottorato     Relatore 
 
Prof. Aldo Roda       Prof. Carlo Bertucci 
 
        
         Relatore 
 
    Prof. Jean-Luc Veuthey 
         Prof. Pierre-Alain Carrupt 
 
 
 
Esame finale anno 2014 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Table of Contents 
 
 
Chapter 1  Introduction       3 
 
Chapter 2 5-Imino-1,2-4-thiadiazoles and quinazolines  15 
derivatives as glycogen synthase kinase 3b 
(GSK-3b) and phosphodiesterase 7 (PDE7) 
inhibitors: determination of binding to human 
serum albumin 
 
Chapter 3 Species-dependent binding of tocainide analogues 35 
to albumin: affinity chromatography and circular 
dichroism study 
 
Chapter 4 Optical biosensor analysis in studying new  63 
synthesized bicalutamide analogues binding 
to androgen receptor 
 
Chapter 5 Bicalutamide analogues interaction with human 83 
serum albumin and rat serum albumin: an affinity 
chromatography and circular dichroism 
investigation 
 
Chapter 6 Optical Biosensor analysis of Bicalutamide  101 
analogues interaction with human serum albumin 
and rat serum albumin 
 
Conclusions          125 
 
Addendum Summary in Italian      129 
 Summary in French      131 
 List of Publications and  Communications   133 
 
 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
 
1.1 General remarks 
 
Understanding the basis of molecular recognition phenomena plays a very 
important role in various fields of chemical research, but surely it becomes of primary 
importance in the context of pharmaceutical research. 
The model of “lock and key” can be assumed in the case of specific biological 
complex formation. When a particular chemical species is located in the neighbourhood 
of another complementary chemical species, the two entities will interact with each 
other to form a biological complex in a selective and dynamic fashion. Many examples 
can be observed among the biological systems, such as DNA-protein, RNA-ribosome, 
enzyme-substrate, antigen-antibody, protein-protein, drug-receptor, etc. 
All the physiological processes are governed by proteins in association with other 
entities. Protein-protein complex formation is the basis of the complex network that 
regulates not only the physiological mechanisms but also the pathological pathways: 
incorrect protein–protein interaction is the molecular switch of numerous diseases [1]. 
These findings explain how the study of the bio-recognition phenomena behind a 
biological process is nowadays considered a useful tool to deeply understand 
physiological mechanisms allowing the discovery of novel biological target and the 
development of new lead candidates [2]. 
Furthermore, in order to be successful, a drug candidate should also possess an 
excellent pharmacokinetic profile, defined by its ADMET parameters. Absorption, 
Distribution, Metabolism, Excretion and Toxicity represent five crucial steps of drug life 
in human body that significantly influence its pharmacological efficacy. In fact, in order 
to reach its site of action a drug must first of all be absorbed into the circulatory system 
from its site of administration; distributed throughout the peripheral tissues; metabolized 
through interaction with specific enzymes located in different body districts (liver, 
intestines, kidneys, lungs, skin, plasma and central nervous system); then eliminated 
completely from the body. In addition, the given drug dose (and its metabolites) must 
not be toxic for our body. 
Recent market surveys have revealed that about half of all drugs in development 
fail to make it to the market because of ADMET deficiencies [3]. So it is clear how the 
interest in the evaluation of pharmacokinetic and toxicological drug properties in early 
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stages of drug discovery is increasing significantly, in order to eliminate as soon as 
possible the looser compounds. To this purpose multiple in silico, in vitro and in vivo 
ADMET experimental approaches have been developed both in industry and academia. 
Surely, the physicochemical parameters of a new chemical entity, such as 
ionization constant, lipophilicity and solubility, dramatically affect the drug bioavailability 
and therefore its toxicological effects [4]. In addition, the plasma proteins binding is also 
closely correlated to the final pharmacological and toxicological success of the new 
drug, as It represents a crucial step for the drug to reach its site of action. 
The monitoring of drug binding to plasma proteins is becoming essential in the 
field of drug discovery to characterize the drug distribution in human body. Human 
serum albumin (HSA) is the most abundant protein in plasma, with a concentration of 
about 600 µM [5]. This protein represents the major serum carrier being responsible for 
the transport of numerous endogenous factors (non-esterified fatty acids, bilirubin, bile 
salts, steroid hormones, hematin, thyroxin, vitamins and metal ions) and various 
xenobiotics (drugs and metabolites), through the formation of non-covalent complexes 
at specific binding sites. The knowledge of drug-HSA interactions is of great importance 
for the pharmacokinetic, pharmacodynamic and toxicological evaluation of a new drug 
candidate [6]. In fact, the unbound drug fraction substantially affects the concentration 
of the drug at its specific receptor site: higher is the binding percentage for the serum 
carrier, lower is the amount of drug available for the pharmacological effect. From this 
point of view this could be considered a drawback, but we have to underline that the 
binding with HSA become a great advantage in presence of poorly soluble compounds: 
their binding to HSA results in improving solubility and sometimes in decreasing toxicity 
[7]. Furthermore, the bound drug fraction acts as a reservoir for a longer drug action, 
increasing its half-life in the human body and maintaining its therapeutic level. 
Because of the ability of this protein to bind numerous different molecules, another 
aspect to be considered is the possible competition between more than one drug or 
endogenous factors that interact with the same HSA binding site: in this case the free 
concentration of the displaced drug changes significantly, thus adversely affecting its 
pharmacokinetics and pharmacological activity [6]. 
Since animal models are often used for pharmacokinetic in vivo experiments, the 
interest in studying the binding of new compounds to albumins from different species is 
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growing. Despite the great similarity between the amino acidic sequences of albumins 
from different animal species, it has already been demonstrated the existence of 
significant interspecies differences. Hence this kind of investigation is very useful to 
evaluate the reliability of extrapolating the distribution data obtained in animals to 
humans [8,9]. 
Therefore, it is clear how the characterization of interactions between proteins and 
drugs determines a growing need of methodologies to study any specific molecular 
event as well as the structural elements that drive the process. 
A wide variety of biochemical techniques have been applied to this purpose. 
Among all, high-performance liquid affinity chromatography (HPALC), circular dichroism 
(CD) and optical biosensor technology represent three techniques that can be able to 
elucidate the interaction of a new drug with its target and with other proteins that could 
interfere with ADMET parameters. 
HPALC is a particular type of affinity chromatography where a biological ligand 
immobilized on the chromatographic support is used as stationary phase. 
In 1990, the HSA-based HPLC columns were first used for the enantiomeric 
resolution of chiral drugs [10]; afterwards there was an increased interest in the use of 
these columns for the characterization of chiral and achiral compounds binding 
processes. Moreover, a large body of literature has extensively demonstrated that the 
HSA maintains the same binding characteristics held in solution also after the 
immobilization process [10-13]. This evidence has made HPALC a reliable technique for 
the study of the interaction between small molecules of pharmacological interest and 
albumins from different species. 
In HPALC zonal elution conditions, the retention of the analyte is a direct evidence 
of the degree of binding for the protein: more strongly bonded compounds show elution 
times longer than those obtained with the weaker bonded compounds. A rapid 
determination of the bound fraction of large libraries of novel synthesized molecules can 
be obtained with this technique, allowing ranking analysis in relatively short times. 
Moreover, in frontal analysis conditions the HPALC technique allows also the 
determination of the association equilibrium constants of the compounds under 
investigation. In this case the analyte passes over the HSA column continuously, 
utilizing a large range of analyte concentrations directly in the mobile phase. 
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The main advantage of this technique is that the chromatographic system can be 
automated in order to obtain reproducibility, precision and speed. The resolution of 
chiral entities obtained with these columns allows also the investigation of the 
enantioselectivity of the binding process. Furthermore, the immobilized HSA column can 
be reused for even long time (almost 1000 injections), resulting in low protein 
consumption [13]. On the other hand, the biochromatographic system detects all the 
interactions that occur with the stationary phase, so the retention time will also be 
affected by the non-specific interactions with the silica matrix itself. The study of 
compounds with very high affinity for the protein (bound fraction > 99%) represents 
another drawback of this technique. This circumstance requires the presence of an 
organic modifier in the mobile phase, which can lead to variations in the protein 
conformation and in the interaction with the drug under investigation [14]. The problem 
could be solved by using very short columns [15].  
Both Circular Dichroism and Biosensor technique represent two different analytical 
approaches based on the monitoring of variations of specific physicochemical properties 
of the protein or of the ligand, when interacting with each other. 
Circular Dichroism (CD) is a spectroscopic technique based on the different 
absorption of the two components of plane polarized light (right and left-hand circularly 
polarized light) by an optically active compound. This phenomenon arises not only when 
the compound under investigation hold chromophores with intrinsic chirality, but also 
when It is located in a chiral environment [16]. This explains why CD is the technique of 
choice for the determination of the absolute configuration of chiral compounds, as well 
as for the characterization of molecular recognition phenomena in solution [6, 17]. The 
literature is full of applications that highlight the value of this technique at different 
phases of drug discovery process [9, 16, 18]. First of all, CD is employed for the 
stereochemical characterization of new drug candidates and therapeutic peptides, in 
order to reliably establish the relationship existing between stereochemistry and 
pharmacological activity [6, 19, 20]. This technique is also widely used to monitor the 
conformational transitions of proteins and peptides, due to secondary structural 
changes functional in various physiological and pathological processes [21-23]. The 
interest towards this type of study has grown after the recent evidence that 
conformational changes of physiological peptides and proteins represent the start 
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button of different neurodegenerative diseases, such as Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease amyotrophic lateral sclerosis and prion 
diseases [24]. 
The CD provides direct information on the binding interaction between a new drug 
candidate and its target protein. It is possible to detect the conformation of the bound 
drug from the CD induced signal obtained upon binding to the target protein and to 
measure also the binding constant of the specific drug-protein interaction, without 
interfering with the equilibrium process. Furthermore, competition experiments carried 
out with this technique provide useful information about the drugs binding sites on the 
target protein and about different co-binding situations that can occur at specific binding 
sites [16]. 
The main advantage of the CD technique is surely the possibility to obtain all these 
information directly in solution, thus avoiding the immobilization step that could 
compromise a reliable investigation of the interaction. Moreover, this technique allows 
us to study the behavior of both enantiomers of chiral drugs. Despite that a huge 
drawback is the relatively large amount of protein necessary to perform a complete set 
of experiments. 
Concerning the Biosensor technology, this technique is responsible for the big 
steps forward seen in the biomolecular interaction analysis field over the last decade. 
The use of Optical Biosensor to characterize target macromolecules and 
biopharmaceuticals is well documented in the current literature [25-27]. The Optical 
Biosensor is based on the optical phenomenon, called Surface Plasmon Resonance 
(SPR). This device consists of three main components: the sensor surface, where one 
of the interacting compounds is attached to; the microfluidic system, to ensure 
reproducible sample consumption and an SPR detector, which measures the change in 
the refractive index close to the surface of the sensor chip, during complex association 
and dissociation. The SPR response observed is proportional to the mass of the analyte 
that is bound to the immobilized ligand. This instrument provides qualitative information 
about the specificity of the binding (Yes/No answer), but also many quantitative data, 
such as the amount of active analyte in the sample, kinetic parameters of the interaction 
(kon, koff) and the affinity constants that characterize the complex formation. Thus, it is 
clear how this technique represents a useful tool in advanced drug discovery stages, 
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where it becomes crucial to have a clear and complete view of the binding mechanisms 
to understand different biological and pathological phenomena [14]. Since the sensitivity 
of this technique is directly related to the mass of the analyte under investigation, it is 
obvious that it will be the technique of choice to study protein-protein interactions. 
Recent improvements in the SPR biosensor have made possible the use of this 
technology also to detect small molecule drugs (< 200 Da). 
The main advantage of this technique is the lack of a labeling step for both the 
ligand and the analyte, thus avoiding extra time and cost or misinterpretation of the 
collected data due to the occlusion of specific binding sites [2]. However, the 
immobilization remains always a critical step, because the immobilized compound may 
take different behavior from that observed in solution. On the other hand the chip can be 
reused even for a long time after the immobilization, depending on the stability of the 
immobilized ligand. This parameter can be also monitored by tracking the surface’s 
binding capacity and the baseline stability during the analysis. Furthermore, the SPR 
biosensor requires short time of analysis and very low sample consumption. 
All the underlined advantages and drawbacks, as well as the various fields of 
application and the different types of information that can be obtained from the 
techniques mentioned above, highlight how the multimethodological approach 
represents the best strategy for the study of molecular biorecognition phenomena, 
especially in advanced stages of drug discovery, giving a detailed and complete 
description of the particular recognition process.   
 
1.2 Aim of the investigation 
 
The main intent of this work is to highlight the importance of the elucidation of the 
biorecognition phenomena existing behind biological processes, since it represents a 
crucial step for the discovery of novel biological target and the development of new lead 
candidates. The investigation involved the use of three orthogonal analytical techniques, 
in order to obtain a clear and complete picture of the particular protein-small molecule 
system. 
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In particular: 
 
 5-Imino-1,2-4-thiadiazoles and quinazolines derivatives as glycogen synthase 
kinase 3b (GSK-3b) and phosphodiesterase 7 (PDE7) inhibitors were characterized for 
their human serum albumin binding, using high-performance liquid affinity 
chromatography and circular dichroism; in order to obtain an evaluation of the drug 
bound fraction to the transport protein and to get information on the high affinity binding 
sites of these compounds to HSA 
 the species-dependent binding of tocainide analogues to two different serum 
albumin (HSA and RSA) were carried out by affinity chromatography and circular 
dichroism, in order to highlight the different binding capacity and stereoselectivity of the 
two similar proteins 
 an optical biosensor analysis has been developed to study the binding of new 
synthesized bicalutamide analogues for their biological target, the androgen receptor; 
thus achieving the affinity constant and the kinetic parameters that drive the specific 
binding process 
 the bicalutamide analogues were also characterized for their HSA and RSA 
binding, by using all the three techniques, i.e. affinity chromatography, circular 
dichroism and optical biosensor. Important differences in the behavior of the two 
proteins were highlighted also in this case. 
 
This study underline the importance of getting in early stages of drug discovery not 
only information about the specificity of a new chemical entity, but also about its 
pharmacokinetic parameters. Moreover, big attention requires the extrapolation of the in 
vivo pharmacokinetic data obtained on animals to humans. The multimethodological 
approach represents the best way to study the biorecognition process and to develop 
the medium-high throughput screening needed in the early phases of drug discovery. 
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5-Imino-1,2-4-thiadiazoles and quinazolines 
derivatives as glycogen synthase kinase 3b (GSK-
3b) and phosphodiesterase 7 (PDE7) inhibitors: 
determination of binding to human serum 
albumin[1] 
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Abstract 
 
5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as glycogen synthase 
kinase 3b (GSK-3b) and phosphodiesterase 7 (PDE7) inhibitors were characterized for 
their human serum albumin (HSA) binding using high-performance liquid affinity 
chromatography (HPLAC) and circular dichroism (CD). For the HPLAC investigation, 
HSA was previously covalently immobilized to the silica matrix of the HPLC column. 
This HSA-based column was used to characterize the high affinity binding sites of 5-
imino-1,2,4-thiadiazoles and quinazolines derivatives to HSA. Displacement 
experiments in the presence of increasing concentrations of competitors known to bind 
selectively to the main binding sites of HSA were carried out to determine their possible 
binding site. The same drug–protein system was studied by CD. 
The analysed compounds showed a high affinity to HSA. Competition experiments 
showed an anticooperative interaction at sites I and II, and an independent binding at 
bilirubin binding site on HSA. 
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2.1 Introduction 
 
Chronic age related neurodegenerative diseases such as Alzheimer’s disease and 
Parkinson’s disease represent a huge and increasing disease burden to society. 
Alzheimer’s disease (AD) is the leading cause of dementia and is predicted to become 
even more prevalent as the proportion of elderly in the population increases over the 
next few decades. There are currently an estimated 5.3 million people with Alzheimer’s 
disease in USA and 5.5 in Europe. It is expected by the year 2050 that the people with 
AD will be four times more. On the other hand, the number of persons with Parkinson’s 
disease (PD) over age 50 in Western Europe’s five most populous nations was up to 4.6 
million in 2005, and this will double to up to 9.3 million by 2030 [2]. 
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase with a critical 
role in neurodegeneration and memory formation. The family consists of two isoforms, a 
and b, which are 98% identical within their kinase domains but differ substantially in 
their N- and C-terminal sequences. GSK-3b is particularly abundant in the central 
nervous system (CNS) and directly phosphorylates several neuronal microtubule-
associated proteins involved in microtubule stabilization. Different studies have 
suggested the central role of glycogen synthase kinase 3b (GSK-3b) in the 
pathogenesis of both sporadic and familial forms of AD [3, 4]. Because of these data, 
inhibition of GSK-3b is a promising strategy for the treatment of AD and other 
neurodegenerative diseases [5]. 
On the other hand, phosphodiesterases (PDEs) selectively degrade cyclic purine 
nucleotides (cAMP and cGMP) that serve as second messengers in a number of 
cellular pathways. PDEs are isoenzymes encoded by at least 22 different genes and 
organized into 11 families (PDE1–11) characterized by molecular biological techniques 
in different mammalian tissues [6, 7]. PDEs have proven to be drug-able targets, with 
compounds on the market or in late-stage clinical development for a variety of diseases 
[8]. Because elevation of the intracellular cAMP level impacts immunosuppressive and 
anti-inflammatory properties [9] treatment of different immune disorders such as Multiple 
Sclerosis, diseases of the central nervous system (e.g., AD, depression) and 
inflammatory processes employing selective inhibitors of cAMP-specific PDEs have 
been widely studied [10-12]. 
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PDE7 is a cAMP-specific PDE family [13], including two members (PDE7A and 
PDE7B). PDE7A is highly expressed in the immune system including spleen, lymph 
nodes and blood leukocytes [14], while PDE7B is abundant in the brain, liver, heart, 
thyroid glands and skeletal muscles [15]. It has been recently published, that PDE7 
inhibition enhances neuroprotection and diminishes neuroinflammation in well-
characterized cellular and animal models of PD [16]. 
For all these reasons, GSK-3b and PDE7 inhibitors play an important role for the 
next future treatment of different neurodegenerative diseases [17, 18]. 5-Imino-1,2,4-
thiadiazoles (Compounds 1-5) [19] and quinazolines (Compunds 6–8) [20] have been 
previously synthesized as potential new drugs for CNS disorders. Their chemical 
structures together with the value of the IC50 on their targets are depicted in Fig. 2.1. 
These compounds were able to inhibit these enzymes at micromolar concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1 A) GSK-3 inhibition of Iminothiadiazoles 1-5. B) PDE7 inhibition of quinazolines 6-8 
 
20 
 
Although the discovery of GSK-3b and PDE7 inhibitors is essential for the 
treatment of severe diseases, it is also important for further pharmacological 
development that these compounds present a favorable Absorption–Distribution–
Metabolism–Excretion (ADME) profile. Determination at early steps of these properties 
is a crucial issue to eliminate weak candidates. 
ADME properties are the major reason for the failure of drug candidates in the late 
stages of drug development, being a serious economic problem in the pharmaceutical 
industry [21]. 
Human serum albumin (HSA, 66 kDa) is the most abundant protein in plasma with 
a concentration of 0.6-0.7 mM [22]. The main role of HSA in plasma is to transport and 
to distribute many substances within the body such as drugs, fatty acids, heavy metals, 
hormones and vitamins. This flexible protein contains numerous potential drug binding 
sites [23]. In pharmaceutical industry it is important to determine and characterize the 
pharmacokinetics and pharmacological effects of drugs. Thus, analysis of the drug 
binding to the most abundant plasma protein is interesting not only because the 
unbound drug fraction affects many critical pharmacokinetic parameters including the 
steady-state distribution volume, but also because it provides useful information to 
design the administration regimen dose. 
Here, the distribution behavior of the 5-imino-1,2,4-thiadiazoles and quinazolines 
families were studied by high-performance liquid affinity chromatography (HPLAC). A 
HSA-based column was used for ranking the compounds under investigation for their 
binding to the serum carrier, and for getting information on the binding areas of the 
studied drugs to the plasmatic protein. The bound fractions of 5-imino-1,2,4-thiadiazoles 
and quinazolines derivatives were determined by measuring their retention on the 
column, using the zonal chromatographic approach. Pivotal displacements experiments 
[24, 25] by adding selected competitors [26] into the mobile phase were carried out to 
individuate the possible binding sites. Results were confirmed by circular dichroism 
(CD) competition studies. 
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2.2 Materials and methods 
 
2.2.1 Chemicals and instruments 
Human serum albumin (HSA) (Cohn fraction V powder essentially fatty acid free, 
A1887), L-tryptophan (L-Trp), glycine, N-benzoyl-DL-leucine, rac-warfarin, sodium 
valproate, rac-ibuprofen sodium salt, sodium salicylate, bromophenol blue, and bilirubin 
were purchased from Sigma–Aldrich (Milan, Italy). Diazepam and clonazepam were 
kindly provided by Prof. Regina H. Costa Queiroz, Faculty of Pharmacy, University of 
San Paolo, at Ribeirao Preto (Brazil). Other chemicals were reagent grade from 
commercial suppliers and were used without further purification. Potassium phosphate 
buffers (PB) were prepared by adjusting the pH of solutions of K2HPO4 with equimolar 
solutions of KH2PO4. K2HPO4, KH2PO4 and (NH4)2SO4 powders were purchased from 
Carlo Erba Reagenti (Milan, Italy). 
The HPLC apparatus consisted of a Jasco PU-2089 plus (Jasco, Tokyo, Japan) 
HPLC pump, a Rheodyne injector system with a 20 µL loop and a Jasco MD-2010 plus 
diode array detector. The column was thermostated at 28 °C with a Column Chiller 
Model 7955 (Jones Chromatography Ltd., UK). 
The chromatographic retention was reported as the capacity factor (k), where k is 
defined as (tdrug - t0)/t0 (tdrug = retention of the solute; t0 = retention of a non-retained 
solute). Buffers were filtered with 0.22 µm mixed cellulose esters filter membranes 
(Millipore, Milan, Italy). The mobile phases were degassed prior to use by ultrasonic 
waves for at least 15 min. Compounds (1-8) were previously synthesized [19, 20]. 
 
2.2.2. Column preparation 
The silica column (50 mm × 4 mm i.d.) packed with Kromasil 200 Å (5 µm) was 
derivatized with 3-glycidoxypropyltrimethoxysilane by an in situ process as previously 
reported [27]. HSA was covalently immobilized on the packed epoxy-silica column by 
the reported [28, 29] online procedure, with slight modifications. In brief, a HAS solution 
(10 mg/mL of protein in 50 mM PB, pH 6.5, 1 M ammonium sulphate) was circulated 
through the epoxy-silica column in closed circuit for 24 h. The column was then washed 
with 120 mL of 50 mM PB, pH 7.4; and 100 mL of 1 M glycine dissolved in PB. The 
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HSA-based column (50 mm × 4 mm i.d.) was employed for the determination of the 
HSA bound fraction and for the displacement studies. 
 
2.2.3. Column evaluation 
Rac-warfarin, and N-benzoyl-DL-leucine, two racemates known to bind HSA 
enantioselectively, were injected into the column in order to check that the immobilized 
protein maintained the binding properties of the native HSA. Stock solutions of the 
racemates were prepared (0.5 mg/mL, 1-propanol), and then diluted 100-fold to the 
appropriate concentration [30 µM] with PB (pH 7.4; 67 mM). The chromatographic runs 
were performed at a flow rate of 1 mL/min, injecting 20 µL of the analytes. Mobile 
phases were PB (pH 7.4; 67 mM)-1-propanol (97:3, v/v) in the case of rac-warfarin and 
PB (pH 7.4; 67 mM)-1-propanol (99:1, v/v) in the case of N-benzoyl-dl-leucine [30]. 
 
2.2.4. Affinity chromatography: bound fraction determination 
Stock solutions of compounds (1-8) were prepared at a concentration of 0.5 
mg/mL in 1-propanol and were diluted 100-fold with PB (pH 7.4; 67 mM) just before 
injection into the HSA column, to reach a final concentration of 30 µM. The mobile 
phase was PB (pH 7.4; 67 mM), and the flow rate 1 mL/min. The bound drug fraction 
(B%) was determined by measuring the capacity factor, according to a previously 
reported method [31]. 
 
       (
 
   
) 
 
2.2.5. Affinity chromatography: displacement experiments 
A series of displacement experiments were carried out to have information on the 
binding site(s) of 5-imino-1,2,4-thiadiazoles and quinazolines. Increasing amounts of the 
markers for the three major binding sites of HSA were added to a mobile phase 
containing PB (pH 7.4; 67 mM). Sodium salicylate, rac-ibuprofen and sodium valproate 
were used as markers of Sudlow’s site I, II and the bilirubin site, respectively. The 
concentration of the marker in the mobile phase ranged from 0 to 100 µM for sodium 
salicylate, from 0 to 50 µM for rac-ibuprofen and from 0 to 3 mM for sodium valproate. 
All the compounds were injected at the same concentration used for the determination 
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of the bound fraction described in Section 2.2.4. The compounds solutions were 
injected and the capacity factors of the drugs were determined in the absence and in 
the presence of increasing concentrations of the competitors. 
The plotting of the reciprocal of the capacity factor (1/k) versus the molar 
concentration of the marker gives information on the interaction mechanism. A direct 
competition at a single site gives a straight line with a positive slope in this plot, while a 
non-competitive relationship gives only random variations [24, 25, 32]. The following 
linear equation is satisfied in the case of direct competition, where the analyte binds to a 
single binding site: 
 
 
  
 
      [ ]
     
 
  
     
         (a) 
 
where kA is the measured capacity factor of the analyte A, VM is the column void 
volume, KI is the association equilibrium constant of the competitor for the single 
binding site of A, [I] is the molar concentration of the competitor, KA is the association 
equilibrium constant of A for its binding site, and mL is the total moles of analyte binding 
sites in the column. This last parameter, mL, corresponds to the protein moles correctly 
anchored to the silica matrix. 
The equilibrium dissociation constant (KD) of the displacer for the single binding 
site of the analyte can be then calculated by linear fitting of the data. 
In particular, KD can be obtained as 
 
         
     
 
 
  
            (b) 
 
Multisite binding determines deviation from this linear behavior. 
To check the dependability of the column and better estimate the entity of 
displacement, warfarin and diazepam were selected as controls when salycilate and 
ibuprofen were used as competitors, respectively. 
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2.2.6. Circular dichroism: displacement experiments 
Circular dichroism measurements were performed with a Jasco J-810 
spectropolarimeter. Displacement experiments were carried out on the compound of 
each family, displaying the highest affinity to HSA in the affinity chromatography study. 
For the 5-imino-1,2,4-thiadiazoles family compound 3 was employed as the competitor, 
and phenylbutazone, diazepam and bromophenol blue as selected markers for site I, 
site II and bilirubin binding site, respectively. The change in the induced CD signal of a 
solution containing equimolar concentrations of HSA and marker [15 µM in PB (pH 7.4; 
67 mM)] was monitored after addition of different amounts of compound 3. For the 
quinazolines family, the opposite approach was employed; the selected compound 6 
was used as a marker, while, warfarin, ibuprofen and valproic acid (selective for site I, 
site II and bilirubin site, respectively) were used as the competitors. The change in the 
induced CD signal of a solution containing equimolar concentrations [15 µM in PB (pH 
7.4; 67 mM)] of HSA and compound 6 after the addition of different amounts of warfarin, 
ibuprofen and valproic acid was monitored. Stock solutions of compound 3 (4.57 mM in 
1-propanol), phenylbutazone (10.37 mM in 1-propanol), diazepam (15 mM in 1-
propanol), bromophenol blue (12.2 mM in 1-propanol) and stock solution of compound 6 
(9.62 mM in 1-propanol), warfarin (20 mM in 1-propanol), ibuprofen (36.8 mM in 1-
propanol), valproic acid (20 mM in 1-propanol) and HSA (409 µM in PB, pH 7.4, 67 mM) 
were prepared immediately before the experiments. All the measurements were carried 
out using a 10 mm pathlength cell. 
5-Imino-1,2,4-thiadiazoles: the working solutions were prepared mixing HSA, 
marker and compound 3 at molar ratios of 1/1/0, 1/1/0.5, 1/1/1, 1/1/2, 1/1/4 and 1/1/8, 
respectively. 
Quinazolines: the working solutions were prepared mixing the HSA, compound 6 
and warfarin at molar ratios of 1/1/0, 1/1/1, 1/1/2, 1/1/4, 1/1/8 and 1/1/16. HSA, 
compound 6 and ibuprofen at molar ratios of 1/1/0, 1/1/4, 1/1/8, 1/1/16, 1/1/24 and 
1/1/32. HSA, compound 6 and valproic acid at molar ratios of 1/1/0, 1/1/4, 1/1/8, 1/1/16 
and 1/1/32. 
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2.3 Results and discussion 
 
2.3.1 HSA bound fraction determination by affinity chromatography 
Prior to the injection into the HSA covalently immobilized column of 5-imino-1,2,4-
thiadiazoles and quinazolines compounds, the reliability of the prepared HSA-based 
column for affinity chromatography studies was checked by injecting racemates of 
molecules known to bind the protein in a enantioselective manner to verify if the protein, 
once anchored to the silica matrix, maintains its binding properties [30]. 
Compounds (1–8) were injected into the HSA column and the ranking for their 
HSA bound fraction was performed on the basis of the capacity factor, k, as determined 
in aqueous solution. Drugs with known bound fraction to HSA (clonazepam, diazepam 
and rac-warfarin) were analyzed under the same experimental conditions to check the 
dependability of the column for ranking the new tested compounds for their HSA binding 
(Tables 2.1 and 2.2). Acetaminophen was analyzed as well as a negative control 
(experimental bound fraction 6.25%, the literature bound fraction < 20%) [33]. A good 
correlation of the HSA bound fraction of drugs between the literature data and the 
experimentally obtained values was obtained. All compounds analyzed showed a high 
affinity to HSA (≥ 94%). In the 5-imino-1,2,4-thiadiazoles family, compounds 2, 4 and 5 
which presented an ethanol chain in their structure, gave lower bound fraction values 
than compound 1, which has not any substituent linked to the nitrogen atom. Compound 
3, with an ethyl ester chain gave the highest bound fraction (B% = 98.3%) to HSA. Note 
that in the quinazolines derivatives, the replacement in the structure of a carbonyl atom 
(compound 8), to the thiocarbonyl one (compound 6), significantly increased the bound 
fraction percentage (94.4% to 99.8%). All these data are valuable to design and 
optimize the synthesis of new compounds to optimize their distribution in the human 
body, giving a better balance between drug distribution and half-life drug. 
 
2.3.2 HSA binding site investigation: displacement affinity chromatography and circular 
dichroism 
Displacement affinity chromatography experiments were carried out by 
determining the capacity factor of each analyte upon increasing concentrations of 
selected competitors added to the mobile phase. The analysis of the chromatographic  
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Table 2.1 
Bound fraction (B%) of the studied compounds obtained by affinity chromatography. 
 
Compound B% by chromatography
a
 B% from literature 
Clonazepam 85.73 ± 0.55 86
b, [33]
 
Diazepam 94.48 ± 0.31 93.5
c, [30]
 
Rac-warfarin 97.80 ± 0.06 98.5
c, [30]
 
1 96.74 ± 0.26 ─ 
2 93.80 ± 0.20 ─ 
3 98.28 ± 0.32 ─ 
4 94.92 ± 0.46 ─ 
5 94.41 ± 0.55 ─ 
6 99.75 ± 0.01 ─ 
7 98.04 ± 0.07 ─ 
8 94.42 ± 0.06 ─ 
a
 Calculated as the average of the results obtained by two or three injections from the equation obtained 
by linear correlation of the experimental and literature B% values of the standards (y = 0.3257x + 68.206, 
r
2
=0.9808). 
b
 In whole plasma.   
c
 Measured by affinity chromatography. 
 
Table 2.2 
KI values obtained by displacement chromatography analysis. The competitor affinity values were 
determined by slope and intercept of the 1/k plot of the analyte upon increasing the concentration of the 
competitor (see equations a and b in section 2.2). 
 
N.S. Variation of k values not statistically significative (P>0.05) 
 
data allowed the affinity constant of the competitors (KI) to be determined (see Section 
2.2). The same methodology described for the bound fraction determination was 
Compound Salicylic acid Ibuprofen Valproic acid 
Clonazepam N.S. ---------- N.S. 
Diazepam ---------- 8.71 x 10
3
 ---------- 
Warfarin 1.01 x 10
4
 ---------- 1.16 x 10
4
 
1 N.S. N.S. N.S. 
2 N.S. N.S. N.S. 
3 3.63 x 10
3
 N.S. N.S. 
4 N.S. N.S. N.S. 
5 N.S. N.S. N.S. 
6 1.16 x 10
4
 2.58 x 10
4
 N.S. 
7 7.78 x 10
3
 2.76 x 10
4
 N.S. 
8 7.29 x 10
3
 1.34 x 10
4
 N.S. 
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employed for the competition studies. The change of the capacity factor (k) was 
monitored upon addition of increasing concentrations of selected competitors into the 
mobile phase. These displacers or competitors were selected because of their specific 
binding sites to human serum albumin such as sodium salicylate (site I), rac-ibuprofen 
(site II) and sodium valproate (site III or bilirubin site) (Table 2.2). 
As an example, the results obtained for one compound of each family (5-imino-
1,2,4-thiadiazole 3 and quinazoline 6) in the competitive experiments binding, together 
with some compounds used as controls (clonazepam, diazepam and warfarin) is 
represented in Fig. 2.2. A significative decrease of the retention times was found in 
compound 3 (5-imino-1,2,4-thiadiazole) and compounds 6–8 (quinazolines) when 
salicylic acid up to 100 µM was used as a displacer. The KI values of the displacers 
obtained are collected in Table 2.2. When salicylate was used as a displacer, 
compounds 1, 2, 4 and 5 from the 5-imino-1,2,4-thiadiazoles family did not significantly 
change their retention time, being the decrease below the statistical significance (P > 
0.05). However in 5-imino-1,2,4-thiadiazole 3 and quinazolines (6–8) a shortening of the 
retention time was observed and the change in the k value was statistically significant 
(P < 0.05). Note that in the case of quinazolines 6–8, the KI values are of the same 
order of magnitude of the affinity constant obtained for the known ligand of site I 
warfarin, suggesting a direct competition. 5-Imino-1,2,4-thiadiazole 3, showed a lower KI 
value suggesting an allosteric competition. 
The employment of ibuprofen up to 50 µM as a displacer showed a decrease of 
the retention time and a statistically significant change in the k value (P < 0.05) in the 
case of quinazolines, while only a small effect, consistent with an allosteric competition, 
was observed for the 5-imino-1,2,4-thiadiazole analogues. Values of KI of the same 
order of magnitude were obtained for quinazolines (compounds 6–8) compared to the 
affinity constant of ibuprofen measured by the known displacer, diazepam, suggesting 
that also site II is involved in the binding of these molecules to HSA. On the other hand, 
very small not statistically significant changes in retention times were found for both 5-
imino-1,2,4-thiadiazoles and quinazolines when valproic acid was employed as the 
displacer up to 3 mM concentration (Table 2.2). 
Since the data showed that both salicylate and ibuprofen compete significantly 
with quinazolines (6–8) for their binding to HSA we can hypothesize that both sites I and  
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a)                                                                         b) 
 
 
 
 
 
 
 
 
 
 
 
                                     c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
II are primarily involved in the binding of these molecules to HSA. Among the 5- imino-
1,2,4-thiadiazoles studied, only the binding of compound 3 was significantly affected by 
the presence of salycilate, and only a weak displacing effect was observed in the 
presence of ibuprofen, suggesting that none of site I and site II is the primary binding 
site of these molecules. An independent binding should be suggested for 5-imino-1,2,4-
thiadiazoles and quinazolines analogues, and valproate, selective marker of the bilirubin 
binding site. 
Competition experiments were also carried out by CD spectroscopy, by monitoring 
the change of the induced CD spectrum observed for a [HSA]/[marker] complex 1:1 (15 
µM) in the presence of increasing concentrations of a selected displacer. Usually a 
known molecule selective for a certain binding site is used as ‘‘marker’’ of that site, 
while the molecule studied is used as ‘‘displacer’’. If the molecule under investigation 
displays an induced CD signal when bound to HSA, the opposite approach, were the 
molecule under investigation is used as ‘‘marker’’ (of its own site(s)), while the known 
molecules are used as ‘‘displacers’’ can be applied as well. The choice of which 
0 1 2 3
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Fig. 2.2 Displacement experiments. Behaviour of 1/k values of Diazepam, Clonazepam, Warfarin and 
compounds 1, 3 and 6 in the absence and in the presence of increasing concentrations of salicylate 
(a), rac-ibuprofen (b) and valproate (c). 
 
29 
 
molecules are to be used as a marker and which as a displacer is made case by case 
depending on the spectroscopic properties of the molecules involved. In the analysis of 
compound 3, the markers employed were phenylbutazone (selective binding to site I), 
diazepam (selective binding site II) and bromophenol blue (selective binding to site III) 
while compound 3 was used a displacer. In the analysis of compound 6, the opposite 
approach was employed and warfarin (site I), ibuprofen (site II) and valproic acid 
(bilirubin site) were selected as displacers and compound 6 as the marker. The 
experiment consists in the determination of the spectroscopic characteristics of the 
involved compounds or the markers-displacers by monitoring the induced CD signal in 
the absence or presence of the competitor [34]. 
In agreement with the results obtained by affinity chromatography, the addition of 
compound 3 showed to displace phenylbutazone (PBU) and diazepam (DZP) from site I 
and site II, respectively only when added at high concentrations, (Fig. 2.3), confirming 
the small anticooperative effect for both sites observed in the affinity chromatography 
displacement experiments. No change was observed in the induced CD spectrum of 
bromophenol blue upon addition of compound 3 up to [HSA]/[marker]/[compound 3] 
1/1/8, confirming the independent binding for 5-imino-1,2,4-thiadiazoles and bilirubin 
site ligands. 
 
 
 
 
 
 
 
 
 
Different results were obtained for quinazoline 6 where a competitive binding at 
sites I and II were found. Both displacers warfarin and ibuprofen were able to change 
significantly the induced CD spectra of [HSA]/[Compound 6], while no significant 
changes were observed when valproic acid was used as displacer (Fig. 2.4). These 
results confirm the affinity chromatography data, indicating that both site I and site II are 
Fig. 2.3 Effect on the induced CD of phenylbutazone (PBU), diazepam (DZP) and bromophenol blue 
(BPB), bound to HSA upon addition of increasing concentrations of compound 3 to the [HSA]/[Marker] 
complexes. Stoichiometry of the [HSA]/[Marker]/[Compound 3] complexes: 1/1/0, 1/1/0.5, 1/1/1, 1/1/2, 
1/1/4 and 1/1/8.  
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involved in the binding of compound 6 to HSA, while an independent binding to bilirubin 
site was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Conclusions 
 
As the proportion of elderly in the population increases over the next few decades 
it is important to discover new drugs for the treatment of diseases whose main risk 
factor is aging such as Alzheimer’s and Parkinson’s disease. Two enzymes implicated 
in the pathogenesis of these diseases are the GSK-3b and the PDE7 respectively. It 
has been recently reported that two families of compounds (5-imino-1,2,4-thiadiazoles 
and quinazolines) are inhibitors of these enzymes. 
Moreover, because the development of drugs for disease treatment requires many 
steps before the drug could be in the market, the evaluation of different pharmacokinetic 
properties at previous stages is recommended to avoid attrition in this process. Thus 
here we evaluated the determination of binding to the most abundant human protein in 
plasma (albumin) of these compounds. All these compounds showed a higher affinity to 
HSA. According to the results obtained by affinity chromatography and CD competition 
experiments, 5-imino-1,2,4-thiadiazoles bind to HSA with a high affinity, at a binding site 
other than the most characterized binding sites of HSA. Results obtained with 
quinazolines suggest that both site I and site II are involved in the binding site of these 
molecules. Both families of compounds showed an independent binding with the 
bilirubin site, suggesting that no interaction between these molecules and bilirubin 
Fig. 2.4 Effect on the induced CD of compound 6 bound to HSA upon addition of increasing 
concentrations of rac-warfarin (WAR), rac-ibuprofen (IBU) and valproic acid (VAL) to the 
[HSA]/[Compund 6] complexes. Stoichiometry of the [HSA]/[Compound 6]/[WAR] complexes: 1/1/0, 
1/1/1, 1/1/2, 1/1/4, 1/1/8 and 1/1/16. Stoichiometry of the [HSA]/[Compound 6]/[IBU] complexes: 1/1/0, 
1/1/4, 1/1/8, 1/1/16, 1/1/24 and 1/1/32. Stoichiometry of the [HSA]/[Compound 6]/[VAL] complexes: 
1/1/0, 1/1/4, 1/1/8, 1/1/16 and 1/1/32. 
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should be evidenced in vivo at this level. Overall the 5-imino-1,2,4-thiadiazoles and 
quinazolines families represent valuable leads compounds to be further studied in 
different preclinical assays as a possible treatment of diverse neurodegenerative 
diseases. 
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Abstract 
 
A series of novel tocainide analogues were characterized for their HSA and RSA 
binding, by using high-performance liquid affinity chromatography (HPLAC) and circular 
dichroism (CD). In this HPLAC study, HSA and RSA were covalently immobilized to the 
silica matrix of HPLC columns, with a procedure that maintained unaltered the binding 
properties of the proteins. The tocainide analogues were ranked for their affinity to HSA 
and RSA on the basis of their bound fractions measured by the two albumin-based 
columns. This technique was also applied to characterize the high affinity binding sites 
of these tocainide analogues to the protein. For this purpose displacement experiments 
were carried out by means of increasing concentrations in the mobile phase of 
competitors known to bind selectively to the main binding sites of HSA. The results 
obtained with the immobilized proteins were confirmed by investigating the same drug-
protein systems in solution by circular dichroism. The comparison of the data collected 
with both methodologies highlighted the dramatic effect of small differences in the 
amino acidic sequences of the two proteins. In fact, despite their similar primary and 
secondary structures, a small difference in the amino acidic sequence leads to 
significant differences in their three-dimensional structure reflecting their different 
binding capacity and their stereoselectivity. Therefore, this study confirms how it is 
crucial to consider the significant differences among the animal models when 
performing pharmacokinetic studies. It is also clear that the knowledge of serum carrier 
binding parameters at an early stage of drug discovery represents a great advantage 
that may help to save time and efforts. 
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3.1 Introduction 
 
The early determination of the absorption, distribution, metabolism, excretion, 
toxicity (ADMET) parameters is fundamental in drug discovery and development [1,2]. 
Drug binding to plasma proteins strongly affects the pharmacokinetic parameters, 
because the actual volume of distribution and concentration of a drug are strictly related 
to its unbound fraction [3,4]. Human serum albumin (HSA) is the most abundant plasma 
protein and has an important role as carrier of exogenous and endogenous compounds 
and as depot of hydrophobic compounds [5,6]. The HSA binding can be altered by the 
concurrent administration of drugs that compete for common or linked binding sites, with 
a significant change of the free fraction, particularly for the highly bound drugs. Since 
this competition may result in toxic levels of free circulating drugs, any new drug 
candidate should be characterized for its affinity to the serum carrier as well as for its 
binding sites location. 
Tocainide is an efficient class Ib antiarrhythmic drug targeting voltage gated 
sodium channels (VGSCs) [7,8]. Unfortunately, tocainide displays off-target activities 
that give rise to serious adverse side effects [9]. 
The tocainide structural framework was selected to create new potent and 
selective sodium channel blockers potentially useful in the treatment of myotonic 
syndromes. [10-12]. In a recent study, a three dimensional quantitative structure-activity 
relationship (3DQSAR) model was built to reveal the stereo-electronic parameters that 
govern the sodium channel block [13]. The resulting pharmacophore hypothesis 
suggested that the combination of the homologated alkyl chain, obtained constraining 
both the stereogenic centre and the terminal amine group of tocainide into a rigid 
pyrrolidine ring (corresponding to a β-prolinic derivative of tocainide, BO3), would result 
in a compound active in the sub micromolar range during use-dependent block. In the 
light of this evidence, and according to the suggestion deriving from the chemometric 
analysis previously reported [13], a new series of tocainide analogues bearing crucial 
modifications at the pharmacophore moieties were synthesized to identify novel 
compounds with a combined increase of both potency and use-dependent behaviour. 
39 
 
Preliminary pharmacological in vitro data were obtained by testing the effect of 
these compounds on sodium currents of adult skeletal muscle fibers measured by 
voltage clamp (data not shown) [14]. 
In a previous work, high performance affinity liquid chromatography (HPALC) and 
circular dichroism (CD) were used to study the binding of a small series of tocainide 
analogues to HSA [15]. The two techniques resulted well suited to determine the 
binding parameters, as previously reported by several authors [16-21]. In the present 
work the same techniques were employed to characterize the binding of a larger series 
of tocainide analogues to rat serum albumin (RSA) and the results were compared to 
those obtained using HSA as the target protein. The data were summarized in a model 
describing the binding sites location of the tocainide analogues on RSA, relatively to 
other drugs (ibuprofen, ketoprofen, diazepam) and bilirubin, which are better 
characterized for their binding sites on HSA. Since the binding of drugs to RSA is yet 
not fully characterized, the data obtained within this work might spread some light over 
the topography of the binding sites of this protein. 
The interest in studying the binding of compounds to albumins from different 
species is related to the wide use of animals, and in particular rats, to perform activity 
and distribution experiments in vivo. A better knowledge of the binding of drugs to 
different albumins will be helpful to evaluate the reliability of extrapolating the 
experimental data obtained with animals to humans [22-25]. 
 
3.2 Experimental 
 
3.2.1 Chemicals and instruments 
Human serum albumin (HSA, essentially fatty acid free, A1887),rat serum albumin 
(RSA, essentially fatty acid and globulin free,A6414), l-tryptophan (l-Trp), glycine, N-
benzoyl-dl-leucine, rac-warfarin, sodium valproate, rac-ibuprofen (IBU), rac-ketoprofen 
(KETO), rac-indoprofen, sodium salicylate (SAL), furosemide, phenylbutazone (PBU) 
and bilirubin (BIL) were purchased from Sigma–Aldrich (Milan, Italy). Diazepam (DZP) 
and rac-oxazepam were kindly provided by Professor Regina H. Costa Queiroz, Faculty 
of Pharmacy, University of San Paolo, at Ribeirao Preto (Brazil). KH2PO4, K2HPO4, and 
(NH4)2SO4 powders were purchased from Carlo Erba (Milan, Italy). Other chemicals 
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were reagent grade from commercial suppliers and were used without further 
purification. Potassium phosphate buffers (PB) were prepared by adjusting the pH of 
solutions of K2HPO4 with equimolar solutions of KH2PO4. 
The HPLC apparatus consisted of a Jasco PU-2089 plus (Jasco,Tokyo) HPLC 
pump, a Rheodyne injector system with a 20 µL loop and a Jasco MD-2010 plus (Jasco, 
Tokyo) diode array detector. The column was thermostated at 28°C with a Column 
Chiller Model 7955 (Jones Chromatography Ltd., UK). Buffers were filtered through 0.22 
µm mixed cellulose esters filter membranes (Millipore, Milan, Italy). The mobile phases 
were degassed prior to use by ultrasonic waves for at least 15 min. 
CD measurements were performed with a Jasco J-810 spectropolarimeter (Jasco, 
Tokyo, Japan) equipped with a Peltier type temperature control system set at 25°C. The 
spectra were recorded using 1 cm pathlength cell at a scan rate of 20 nm/min, time 
constant 2 s, resolution 0.2 nm, and spectral bandwidth 1 nm. 
 
3.2.2 Tocainide analogues, synthesis and physico-chemical properties 
Synthesis and physicochemical characterization of the tocainide (Toc) analogues 
BO1, BO2, BO3, Toc (Tocainide), BO5, BO6, BO7,BO8, BO9, BO10, BO11, BO12, 
BO13, BO14 have been described elsewhere [14,15]. The structures of the compounds 
are reported in Fig. 3.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1 Structures of tocainide and its analogues. 
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3.2.3 Columns preparation 
The silica monolithic columns (50 mm × 4.6 mm i.d.), 20 nm mesopores, were 
silanized by an in situ process as previously reported [15] with slight modification. In 
brief, the monolithic columns encased in a PEEK plastic cover were dried at 120°C for 6 
h under helium. After cooling, the columns were flushed with dry toluene (10 mL) at 0.5 
mL/min. The columns were then heated up to 100°C, and derivatized in situ by pumping 
through a solution of 3-glycidoxypropyltrimethoxysilane (10 mL in 90 mL of toluene) at 
0.5 mL/min to give an epoxide silica column. After cooling the columns were washed 
with anhydrous toluene (10 mL) and anhydrous acetonitrile (20 mL) at 0.5 mL/min.  
HSA and RSA were covalently immobilized online on the monolithic epoxy-silica 
columns following a previously reported procedure [26]. In brief, either HSA or RSA 
solutions (10 mg/mL of protein in PB (50 mM, pH 6.5), 1 M ammonium sulphate) were 
circulated through the epoxy-silica columns in closed circuit for 24 h. The columns were 
washed with 120 mL of PB (50 mM, pH 7.4), and 100 mL of 1 M glycine dissolved in PB 
(50 mM, pH 7.4). The columns were then washed with PB (67 mM, pH 7.4)/1-propanol 
95:5 and stored at 4°C until use. The two albumin-based columns were employed for 
the determination of the bound fractions of the studied compounds. The RSA-based 
column was also used for the displacement studies on the compounds under 
investigation. 
 
3.2.4 Columns characterization 
The columns were characterized in terms of amount of albumin correctly 
immobilized by the frontal analysis of l-tryptophan as previously reported [26,27] for the 
HSA-based column and of lidocaine for the RSA-based column. A series of solutions of 
l-Trp in PB (67 mM, pH 7.4) ranging from 12.5 µM to 100 µM (HSA column), and of 
lidocaine in PB (67 mM, pH 7.4) ranging from 5 µM to 50 µM (RSA column), were 
continuously applied to the columns as mobile phases. The relevant breakthrough 
volume (V −V0) of each solution, where V is the breakthrough volume and V0 is the 
system void volume, was determined and the following linear equation was applied [27]: 
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where [analyte] is the molar concentration of L-tryptophan or lidocaine, 
      represents the moles of analyte required to reach the mean position of the 
breakthrough curve at a given concentration of applied analyte (so it is equal to 
(    )  [     ]), KA is the association equilibrium constant of the analyte for the 
binding to its single site, and mL represents the moles of binding sites available for the 
binding of L-Trp or lidocaine. The equation assumes that the analyte binds to a single 
site on the protein and that bound and free species are constantly in equilibrium (i.e. the 
association and dissociation kinetics of the complex are sufficiently fast). If the equation 
is satisfied (i.e. the relationship is linear) mL is equal to the moles of correctly 
immobilized proteins present in the columns [27]. The y-axis intercept corresponds to 
the reciprocal of the moles of immobilized protein, while the ratio of the intercept to the 
slope yields the KA of the analytes. These affinity values may be compared to the data 
present in literature as a first evaluation of the goodness of the immobilization. 
A series of racemates reported to bind the proteins in a stereoselective manner 
(rac-oxazepam, rac-warfarin, rac-indoprofene and N-benzoyl-DL-leucine) were used to 
check the dependability of the albumin-based columns. Stock solutions of the 
racemates prepared 0.1 mg/mL in 1-propanol were diluted with PB (67 mM, pH7.4) and 
injected into the columns. Mobile phases were mixtures of PB (67 mM, pH 7.4)/1-
propanol. 
 
3.2.5 Bound fraction determination 
Stock solutions (1 mM) were prepared in 1-propanol. Working solutions were 
prepared just before injection into the columns, by diluting the stock solutions with PB 
(67 mM, pH 7.4). The concentration of working solutions was 20 µM, but it has been 
increased up to 30 µM when peak broadening (due to high retention into the column) 
combined with weak UV absorbance lowered the signal to noise ratio below 3. 
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The chromatographic retention was reported as the capacity factor (k’) and its 
logarithm (log k’), where k’ is defined as 
 
0
0
'
t
tt
k
drug 
            (3.2) 
 
(tdrug= retention of the solute; t0= retention of an unretained solute). Samples were 
analyzed in duplicate or in triplicate. The flow was set at 1 mL/min. The k’ values were 
determined in absence or presence of 1-propanol, added to the mobile phase at several 
concentrations. Mobile phases were composed of PB (67 mM, pH7.4)/1-propanol 
ranging from 90:10 to 100:0. The retention values were plotted as log k versus the 
organic modifier concentration. The bound fraction (B%) was determined from the 
capacity factor k’ measured in absence of 1-propanol, according to a previously 
published method [28]. 
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The method should be validated by analysing drugs with known bound fraction to 
the protein. 
 
3.2.6 Displacement experiments 
The capacity factor k’ of the studied compounds was measured in presence of 
increasing concentrations in the mobile phase (PB 67 mM, pH 7.4) of sodium salicylate 
(SAL), rac-ibuprofen (IBU) and sodium valproate (VAL), which are markers of Sudlow’s 
site I, II and the bilirubin site, respectively on HSA. The concentration of the marker in 
the mobile phase ranged from 0 to 80 µM for SAL, from 0 to 20 µM for IBU and from 
0.25 to 1.5 mM for VAL. All the compounds were injected at the same concentration 
used for the determination of the bound fraction described in Section 3.2.5. 
By plotting the reciprocal of the capacity factor (1/k’) against the molar 
concentration of the marker, the relationships between the analyte and the marker can 
be determined: direct competition at a single site yields a straight line with a positive 
slope, whereas anon-competitive relationship lacks of correlation [3,16,29]. In the 
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simplest case of direct competition, where the analyte A has a single binding site, the 
following linear equation is satisfied [17]: 
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where kA’ is the measured capacity factor of the analyte A, VM is the column void 
volume, KI is the association equilibrium constant of the displacer I for the single binding 
site of A, [I] is the molar concentration of the displacer, KA is the association equilibrium 
constant of A for its binding site, and mL is the total moles of binding sites of A in the 
column. It follows that the equilibrium association constant of the displacer for the 
analyte binding site, KI, can be calculated by linear fitting of the data from the ratio of 
the slope to the intercept. Deviations from this linear behaviour can be seen for multisite 
binding. 
 
3.2.7 Circular dichroism: displacement experiments 
The displacement experiments were carried out using compounds BO3 and BO14 
as the competitors, and phenylbutazone (PBU), diazepam (DZP), rac-ketoprofen 
(KETO) and bilirubin (BIL) as markers for Site I, Site II and bilirubin binding site, 
respectively. The change in the CD signal after addition of different amounts of 
compounds BO3 and BO14 to a solution containing equimolar concentrations of RSA 
and marker [15 µM in PB (pH 7.4; 67 mM)] were monitored. Stock solutions of 
compounds BO3 and BO14 (10 mM in 1-propanol), PBU (15 mM in 1-propanol), DZP 
(15 mMin 1-propanol) and RSA (150 µM in PB, pH 7.4, 67 mM) were prepared 
immediately before the experiments. The stock solution of BIL (1 mL) was prepared by 
dissolving the powder in KOH (1/5 of the final volume), then adding sequentially 
K2HPO4 0.1 M (1/5 of the final volume) and water (3/5 of the final volume). The final 
concentration of BIL stock solution was 7.5 mM and was prepared immediately before 
use. All the measurements were carried out using a 10 mm path length cell. The 
working solutions were prepared by mixing RSA, marker and displacers at molar ratios 
from1:1:0 up to 1:1:10. 
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3.3 Results and discussion 
 
3.3.1 Column characterization 
The HSA- and RSA-based columns were characterized by frontal analysis in order 
to determine the amount of protein immobilized onto the column. The plot of the bound 
analyte versus the reciprocal of its concentration (see Section 2.4) was used to 
determine the amount of albumin correctly anchored to the silica matrix, and the affinity 
constants of the analytes for the albumins. As previously observed, L-Trp showed to 
bind to a single site on albumin (r2= 0.9988) [27] with a KA of 0.99 (±0.15) × 10
4 M−1,in 
agreement with the value of 1 × 104 M−1 reported in the literature [5]. Lidocaine 
demonstrated to bind to a single site on RSA (r2= 0.9985) as previously observed for 
HSA [30]. The KA for lidocaine binding to RSA was 1.21 (±0.20) × 10
4M−1, which was 
consistent with the relatively weak binding reported earlier for HSA [30]. The amount of 
immobilized albumin was 18.4 (±2.3) mg for the HSA column and 20.2 (±3.0) mg for the 
RSA column. Considering an amount of silica of about 0.25 g per column the amount of 
protein immobilized resulted in about 74 mg/g silica and 81 mg/g silica for HSA and 
RSA, respectively. 
By injecting racemates of drugs or amino acids reported to bind the protein in a 
stereoselective manner (rac-ketoprofen, rac-ibuprofen, rac-indoprofen, rac-oxazepam, 
rac-warfarin and N-benzoyl-DL-leucine) we also checked that the immobilization 
procedure preserved the native binding properties of the proteins. In fact the 
enantioresolution was obtained for all the analyzed racemates (see, as an example, Fig. 
3.2). 
 
3.3.2 Bound fraction determination 
Tocainide and its analogues were injected into the columns containing HSA and 
RSA covalently immobilized. The ranking of the tocainide analogues for their HSA and 
RSA bound fractions was performed on the basis of the capacity factor, k’, as 
determined in aqueous solution (Table 1). Only the enantiomer with higher affinity was 
considered for racemic compounds that showed enantioselectivity in the binding to the 
protein. The dependability of the columns for ranking the new synthesized compounds  
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for their HSA and RSA binding was checked by analysing in the same experimental 
conditions some compounds, whose bound fraction to the serum proteins was already 
known. A quite good agreement was obtained in the comparison of the bound fraction of 
the selected drugs between experimental and literature binding data. As an example, 
the lower affinity (bound fraction) of diazepam to immobilized RSA compared to the 
immobilized HSA matched the different affinity for the two proteins measured in solution 
[22]. 
All the tocainide analogues showed a higher affinity to HSA and RSA when 
compared to the parent compound, Toc (tocainide,Table 3.1), and, among all the 
analogues, compound BO6 exhibited the highest affinity (bound fraction) to both the 
albumins. Tocainide (Toc), BO11 and BO12 have log P values significantly lower with 
respect the other analogues, thus suggesting the importance of the hydrophobicity as a 
parameter affecting the binding process. As already underlined in a previous study, 
there is a general tendency for the analogues with higher log P to bind tighter to albumin 
[21]. However the lack of a simple linear correlation, suggests that the overall 
lipophilicity is not the only parameter affecting the binding of these molecules to albumin 
(Table 3.1). The constriction of the amino group into a rigid pyrrolidine moiety, and the 
nature of the aromatic moieties, affects the affinity, each structural part giving a different 
contribution to the binding to the two proteins. As whole, significant differences were  
 
 
Fig. 3.2 (A) Chromatographic enantioresolution of rac-warfarin 0.01 mg/mL on HSA column; (B) 
chromatographic enantioresolution of rac-indoprofen 0.04 mg/ml on RSA column. Mobile phases were 
phosphate buffer (pH 7.4; 67 mM)/1-propanol (92:8, v/v) and (98:2, v/v), respectively. The runs were 
monitored at λ = 308 nm (rac-warfarin), and at λ = 260 nm (rac-indoprofen). 
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Table 3.1 
Ranking and bound fraction (B%) data obtained with HSA and RSA by affinity chromatography compared 
with literature data and predicted log P values. 
 
N.D. Not determined. 
a [35]. 
b [15]. 
c [36]. 
d Higher affinity enantiomer. 
 
observed in the binding of tocainide and its analogues to HSA and RSA (Table 1), being 
the binding to HSA generally stronger than to RSA. These differences were even more 
impressive when the free fractions were considered instead of the bound fractions 
Sample 
Ranking 
HSA 
Ranking 
RSA 
B% HSA B% RSA Log P
a
 B% HSA Lit. 
BO1 11 11 88.3 81.5 3.11 ±0.34 89.1
b
 
BO2 10 8 N.D. 95.4
d
 3.42 ±0.40 94.5
b
 
BO3 5 9 97.2 93.6 3.03 ±0.36 97.1
 b
 
Toc 14 14 N.D. 36.0 1.04 ±0.49 25.4
b
 
BO5 3 4 98.2 96.7 4.00 ±0.45 98.1
 b
 
BO6 1 1 N.D. 99.1
d
 4.57 ±0.47 99.3
 b
 
BO7 2 2 98.3 97.9 3.39 ±0.07 98.3
 b
 
BO8 8 5 95.4 96.9
d
 4.22 ±0.31 - 
BO9 9 10 95.3 87.9 3.34 ±0.39 - 
BO10 4 7 N.D. 95.6 2.80 ±0.07 97.7
 b
 
BO11 13 12 34.7 43.5 1.28 ±0.52 - 
BO12 12 13 38.0 43.5 1.24 ±0.52 - 
BO13 6 6 96.7 96.0 4.42 ±0.41 - 
BO14 7 3 95.8
d
 97.7 4.22 ±0.31 - 
R-warfarin - - 98.3
 b
 97.2 - 99±1
c
 
S-warfarin - - 98.7
 b
 98.4 - 98.6±0.4
c
 
Furosemide - - N.D. 98.8 - 93.5
 b
 
Diazepam - - 94.8 89.5 - 98.7±0.2
c
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(Table 3.2). However some similar patterns for the affinity to the two proteins driven by 
the type of substitution were recognized. In particular, the 1C-elongation of the side 
chain (Toc → BO11 and BO12) showed only a slightly higher binding to both HSA and 
RSA than the parent compound (Toc) while the substitution of the amino group with an 
aromatic moiety (Toc → BO1, BO8 and BO14) dramatically increased the binding to 
both the albumins. The combination of chain elongation and amino substitution had an 
additive effect when the aromatic was a benzyl group (BO1 → BO9) while the 
elongation gave a much lower contribution when the aromatic was a naphthyl group 
(BO8 → BO13), for binding to HSA and RSA. Conversely, when the amino group was 
constricted into a rigid ring, the chain elongation, obtained substituting the α-proline side 
chain with a β-proline (BO2 → BO3), gave a contribution only on the binding to HSA. 
Interestingly the substitution of a α-naphthyl to a β-naphthyl on the amino group (BO8 
→ BO14) gave opposite effects on the binding to HSA and RSA, decreasing the affinity 
to the former and increasing the affinity to the latter. Since the actual volume of 
distribution and the concentration of a drug at the receptor site is related to the drug free 
fraction [3,4], the characterization of the binding process is essential to understand the 
pharmacokinetic, pharmacodynamics, and toxicological profile of the drug. This aspect 
is particularly relevant for relatively highly albumin bound drugs, where small changes in 
the bound fractions have a significant impact on the free fractions. As an example, the 
bound fractions of BO5 are 98.1% for HSA and 96.7% for RSA; this corresponds to 1.7-
fold difference in the free fraction of the same compound for the two albumins. 
Analogously we have a 2.6-fold free fraction of BO3 with RSA while we have a 2.1-fold 
free fraction of BO14 with HSA. 
Thus these data support the importance of collecting drug binding data with 
albumins from different species, to ensure the reliability of extrapolating to men 
distribution data obtained on animals in preclinical studies.  
It is known that the presence of an organic solvent may affect the drug–protein 
binding process, either by triggering a general change in the secondary or tertiary 
structure of the protein, and/or modifying the microenvironment at the binding site(s) so 
that low energy interactions (hydrophobic and dipole–dipole interactions, coulombic 
forces, hydrogen bonds) cannot take place. A careful observation of the variation of log 
k’ values of the tocainide when changing the propanol concentration in the mobile 
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Table 3.2 
Comparison between the free fraction (F%) obtained with HSA and RSA by affinity chromatography. 
 
a
 [15]. 
b
 Higher affinity enantiomer. 
 
phase (Fig. 3.3) revealed some particular features: in presence of propanol all 
compounds showed a nearly linear relationship between log k’ and the organic solvent 
concentration, while without propanol the log k’ values suddenly increased without 
respecting this linear relationship (Fig. 3.3). Interestingly the binding of some of the 
compounds seemed to be slightly more affected by the presence of 2%propanol, than 
others. This behaviour allowed a subdivision of the compounds into two groups: the 
compounds whose binding was less sensitive to the presence of propanol (Fig. 3.3A) 
and those whose binding was more sensitive to the presence of the organic solvent 
(Fig. 3.3B). All the compounds bearing a β-proline ring (BO3, BO5,BO6, BO7, BO10) 
and BO9 belonged to the group more sensitive to the presence of propanol, while all the 
Sample F% HSA F% RSA F% RSA/HSA 
BO1 11.7 18.5 1.64 
BO2 5.5
a
 4.6
b
 0.84 
BO3 2.8 6.4 2.27 
Toc 74.6
 a
 64.0 0.86 
BO5 1.8 3.3 1.73 
BO6 0.67 0.87
b
 1.30 
BO7 1.7 2.1 1.26 
BO8 4.6 3.1
b
 0.67 
BO9 4.7 12.2 2.56 
BO10 2.3
 a
 4.4 1.90 
BO11 65.3 56.5 0.86 
BO12 62.0 56.5 0.91 
BO13 3.3 4.0 1.21 
BO14 4.2
b
 2.3 0.55 
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others (BO1, BO2, Toc, BO8,BO11, BO12, BO13, BO14) and DZP showed a lower 
sensitivity. A strikingly similar variation of log k’ passing from 0 to 2% of propanol was 
exhibited by all the compounds belonging to the same group (Fig. 3.3A and B). Besides, 
a significant difference was observed in the behaviour of the two groups (Fig. 3.3C), 
even though this difference was extremely low. This strikingly similar sensitivity to 
propanol between molecules, which was already observed for some HIV protease 
inhibitors binding to HSA [26], clearly indicate that the molecules belonging to the same 
group share common properties related to their binding to the protein and that this 
property is affected by the presence of organic solvent. The sensitivity to the organic 
solvent may be indicative of the solvent accessibility to the binding site(s), the overall 
pattern of bonds created between the molecules and the protein, small conformational 
changes of the protein at the binding site level, or all of them at the same time. Thus 
molecules showing the same sensitivity might share the same binding site(s) and the 
same type of bonds. This hypothesis, supported by the results obtained from the 
displacement experiments (see next section), suggests that the compounds within the 
same group bind to the same region(s) on the protein, and that they have one or more 
binding properties that differs from the molecules of the other group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3 Relationship between log k’ values of diazepam and tocainide analogues obtained with the 
RSA-based column at various concentrations of 1-propanol in the mobile phase. (A) Compounds 
showing a binding less sensitive to the presence of 2% organic solvent in the mobile phase. (B) 
Compounds showing a binding more sensitive to the presence of 2% organic solvent in the mobile 
phase. (C) Comparison between the profiles of log k’ versus propanol concentration of selected 
compounds belonging to the two different groups; the picture highlights the similar slope between 0 
and 2% of organic solvent showed by compounds belonging to the same group and the difference to 
the other group: the similar higher slope showed by BO3 and BO5 compared to BO2 and BO14, 
indicate a similar higher reduction of affinity caused by the organic solvent for the formers compounds 
and a similar lower reduction of affinity for the latters. 
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3.3.3. Albumin binding site investigation by displacement affinity chromatography 
In a previous work, displacement affinity chromatography and CD experiments 
carried out for some of tocainide analogues showed a non-cooperative binding at site I 
and site II and an almost independent binding at bilirubin binding site on HSA [21]. Thus 
these sites are not the primary binding site on HSA for the tocainide analogues studied. 
The same chromatographic investigation was carried out in this work for their binding to 
RSA, by determining the capacity factor (k’) of each compound upon increasing 
concentrations of selected competitors added to the mobile phase. The analysis of the 
chromatographic data allowed the affinity constant of the competitors for the binding 
site(s) of the analytes (KI) to be determined (see Section 3.2). The competition studies 
were performed using the same system described for the bound fraction determination. 
The selected displacers were the same used for HSA, i.e., sodium salicylate (SAL, site 
I), rac-ibuprofen (IBU, site II) and sodium valproate (VAL, site III, known also as bilirubin 
site). The displacements of some of the analyzed compounds (BO1, BO7, BO8, BO10, 
BO13, BO14) in the presence of increasing concentration of SAL are reported in Fig. 
3.4 and in Table 3.3. The retention of tocainide analogues decreased when adding SAL 
in the mobile phase up to 75 µM. The KI value for SAL, as determined on the basis of its 
competition effect, was always much lower than that expected in case of a direct 
competition (Table 3.3). Indeed the KI measured when (S)-WAR, (R)-WAR and 
furosemide, which are supposed to bind to site I on RSA [31] were used as the analyte 
was in the order of 104 M−1. This behaviour suggests an allosteric competition with a 
non-cooperative binding of tocainide analogues with SAL. A similar situation was 
observed when IBU was used as the competitor. The displacement of compounds BO8, 
BO13 andBO14 in the presence of increasing concentration of IBU is shown in Fig. 
3.5A. A retention decrease upon increasing concentrations of IBU in the mobile phase 
was observed for the analyzed compounds. In all the cases, the affinity constant 
calculated for the binding of IBU to the compounds binding site(s) (KI) was relatively 
low, compared to the expected value in the order of 106 M−1 [31] that should have been 
obtained in the case of a direct competition for the primary binding site of IBU (Table 
3.3). However, the presence of secondary binding sites for IBU on RSA with a KA in the 
order of 104 M−1 has been previously suggested [31], thus the KI values obtained are 
consistent with either an anticooperative binding to the primary binding site of IBU or 
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with a direct competition to one or more secondary binding sites of IBU. In this latter 
case the small displacement monitored would be the effect of the small fraction of IBU 
that binds the secondary site(s) in the range of concentrations used in the experiments. 
These results also confirm that DZP binds to a site different from the primary binding 
site of IBU, as previously suggested [31,32]. Interestingly, the compounds belonging to 
the group more sensitive to the presence of propanol showed a KI lower than the KI 
measured for the components of the other group (Table 3.3), thus supporting the 
hypothesis that the compounds belonging to the same group have the same binding 
properties. To summarize, these results suggest that both Site I and the primary binding 
site of IBU are not primary binding sites for the analyzed compounds. However, further 
experiments by CD (see later in this section) confirm the differences between profens 
and benzodiazepines binding sites on HSA and RSA. Finally, insignificant changes of 
the retention times were observed when valproate was used as the displacer up to 1.5 
mM for most of the analogues (Fig. 3.4B). Very low KI values were obtained only when 
compounds BO8 and BO14 were used as the analytes (Table 3.3). Thus, an almost 
independent binding should be suggested for tocainide analogues when VAL was used 
as selective marker of the bilirubin binding site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.4 Affinity chromatography displacement 
experiments carried out in the presence of 
increasing concentration of salicylate (SAL) on 
the RSA column. (left) Displacementprofiles of 
compounds BO7, BO8, BO10, BO13, BO14. 
(right) Displacement profiles of standard 
compounds. 
 
Fig. 3.5 Affinity chromatography displacement 
experiments on the RSA column. (left) 
Displacement profiles of compounds BO8, 
BO13 and BO14 in the presence of 
increasingconcentration of rac-ibuprofen (IBU). 
(right) Displacement profiles of compounds 
BO8 and BO14 in the presence of increasing 
concentration of valproate (VAL). 
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Table 3.3 
The competitor affinity values (KI) values obtained by displacement chromatography analysis. 
 
Sample KI Salicylate KI Ibuprofen KIValproate 1-propanol sensitivity 
BO1  2.75 x 10
3
 1.30 x 10
4
 Not significant – 
BO2 N.D. 2.70 x 10
4
 N.D. – 
BO3 N.D. 5.35 x 10
3
 Not significant + 
Toc N.D. N.D. N.D. – 
BO5 N.D. 7.39 x 10
3
 Not significant + 
BO6 N.D. N.D. N.D. + 
BO7 1.27 x 10
3
 4.27 x 10
3
 Not significant + 
BO8 3.12 x 10
3
 1.47 x 10
4
 2.31 x 10
2
 – 
BO9 N.D. 5.36 x 10
3
 Not significant + 
BO10 2.01 x 10
3
 Not Significant Not significant + 
BO11 N.D. N.D. N.D. – 
BO12 N.D. N.D. N.D. – 
BO13 Not significant 9.69 x 10
3
 Not significant – 
BO14 5.16 x 10
3
 2.49 x 10
4
 3.69 x 10
2
 – 
Diazepam 1.76 x 10
3
 2.21 x 10
4
 1.52 x 10
2
 – 
R-warfarin 1.62 x 10
4
 N.D. 1.79 x 10
3
  
S-warfarin 2.1 x 10
4
 N.D. 2.73 x 10
3
  
Furosemide 1.62 x 10
4
 N.D. 1.45 x 10
3
  
 
54 
 
3.3.4. Albumin binding site investigation by circular dichroism 
Competition experiments were also carried out with RSA in solution by CD 
spectroscopy. The experiments consisted in monitoring the change of the induced CD 
spectrum observed for a [RSA]/[marker] complex 1:1 (15 µM) in the presence of 
increasing concentrations of the competitors. In general CD competition experiments for 
protein binding studies can be carried out using competitors known to bind to specific 
binding sites, as it was done for the affinity chromatography experiments. Alternatively 
the compound under investigation can be used as the competitor, and analyzed against 
specific markers known to bind to specific binding areas. In our experiments compounds 
BO3 and BO14, selected as representative of each group of the tocainide analogues, 
were used as the competitors. The strategy of the experiment is determined by the 
spectroscopic characteristics of the involved compounds, being the measurements 
based on the monitoring of the induced CD signal in the absence and in the presence of 
the competitor [18]. In order to make easier the analysis of the data, the marker should 
present absorption and an induced CD signal at lower energy with respect to the 
absorption of the competitor and of the protein [18]. The markers employed were 
phenylbutazone (PBU, selective binding to site I on HSA), diazepam and rac-ketoprofen 
(DZP, KETO, selective binding to site II on HSA) and bilirubin (BIL, selective binding to 
bilirubin site). 
The addition of increasing concentrations of compounds BO3 and BO14 up to a 
molar ratio [competitor]/[marker] 8/1 determined a blue-shift of the induced CD spectrum 
of [RSA]/[PBU] 1/1 complex (Fig. 3.6). This result suggests an allosteric interaction 
between the site I marker and competitors, without a significant displacement of the 
marker, consistently to the results obtained by affinity chromatography. When rac-
ketoprofen (KETO) was used as the marker, the induced CD spectrum of [RSA]/[KETO] 
1/1 complex was unaffected by the presence of BO3 up to [competitor]/[marker] 10/1 
molar ratio, while the presence of compound BO14 decreased the intensity of the 
induced CD signal proportionally to the added concentration, indicating a direct 
competition of BO14 for the stereoselective binding site of ketoprofen (Fig. 3.7). Both 
BO3 and BO14 were able to partially displace diazepam from its stereoselective site 
(Fig. 3.8). In the case of BO3, the maximum displacement was obtained at 
[competitor]/[marker] 8/1, while in the case of BO14 a similar maximum displacement 
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was obtained at [competitor]/[marker] 1/1. The higher displacement efficiency showed 
by BO14 might reflect its higher affinity, as suggested by the higher bound fraction 
measured in the affinity chromatography experiments. However, since the small 
induced CD signal characteristic of the complex [DZP]/[RSA] 1:1 is significantly affected 
by background noise, this information should be considered only qualitative. The 
different competition observed at the profens and benzodiazepines binding sites 
indicated that the site II on RSA is different from that of HSA, with a probable different 
location of diazepam and ketoprofen binding sites in the same binding area [32]. To 
better clarify the binding site locations, rac-ibuprofen (IBU) was tested as competitor 
against [RSA]/[DZP] and [RSA]/[KETO] 1:1 complexes. IBU showed to competitively 
displace diazepam from its stereoselective binding site and the induced CD signal of 
[RSA]/[DZP] complex at 320 nm was null at [competitor]/[marker]4:1 (Fig. 3.9A). At the 
same time a small induced CD signal of the complex [RSA]/[IBU] proportional to the 
concentration of IBU added to the solution became evident at wavelengths below 305 
nm, especially at higher concentrations of IBU (Fig. 3.9B). Considering that the KA of 
IBU for its primary site [31] is about 40-fold higher than the KA of DZP for its 
stereoselective binding site [22], a much more efficient displacement was expected in 
case of a direct competition for the binding at the same primary site. Thus these results 
are consistent with the partial displacement of DZP observed when IBU was used as 
competitor in the affinity chromatography displacement experiments. When added to the 
complex [RSA]/[KETO] 1:1 up to [competitor]/[marker] 2:1, IBU showed only a small 
effect on the stereoselective binding of KETO, while a further addition up to 
[competitor]/[marker] 4:1 was responsible of a significant displacement of KETO from its 
stereoselective binding site that continued in a competitive trend upon further increase 
of the concentration of IBU (Fig. 3.9C). However, even the addition of 
[competitor]/[marker] 12:1 did not displace completely ketoprofen from its 
stereoselective binding site. As observed for the displacement of DZP, a small induced 
CD signal of the complex [RSA]/[IBU] proportional to the concentration of IBU was 
visible at wavelengths below 305 nm. These results suggest that ketoprofen and 
ibuprofen do not share a common primary binding site on RSA, but they have still a 
binding site in common, drawing a furthermore complex picture of the location of 
profens/benzodiazepines binding sites on this albumin. 
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Finally, a contemporary reduction of the intensity and a blue-shift were observed in 
the induced CD spectrum of BIL upon addition of both compounds BO3 and BO14 up to 
a [competitor]/[marker] 8/1 and 10/1 molar ratios, respectively (Fig. 3.10A), followed by 
a small but linear reduction of the UV of BIL (Fig. 3.10B). Differently from the complex 
HSA/BIL, where only the intensity of the induced CD signal change when varying the  
 
Fig. 3.8 Effect on the induced CD spectrum of 
diazepam (DZP) bound to RSA (15 µM) upon 
addition of increasing concentration of compounds 
BO3 and BO14 to the [RSA]/[DZP] complex. 
Stoichiometry of the [RSA]/[DZP]/[competitor] 
complexes are:1/1/0 (black), 1/1/0.5 (blue), 1/1/1, 
1/1/2, 1/1/4, 1/1/8, 1/1/10, green colour scale, for 
BO3 and 1/1/0 (black), 1/1/0.5 (blue), 1/1/1, 1/1/6, 
1/1/8, green colour scale for BO14. The arrows 
indicate the direction of the shift caused by the 
increase of competitor concentration. 
Fig. 3.6 Blue-shift of the induced CD 
spectrum of phenylbutazone (PBU) bound to 
RSA (15 µM) upon addition of increasing 
concentration of compounds BO3 (top) and 
BO14 (bottom) to the [RSA]/[PBU] complex at 
stoichiometry [RSA]/[PBU]/[competitor]: 1/1/0 
(black), 1/1/1, 1/1/4, 1/1/8, green colour scale. 
The arrows indicate the direction of the shift 
caused by the increase of competitor 
concentration. 
 
Fig. 3.7 Effect on the induced CD spectrum of 
ketoprofen (KETO) bound to RSA (15 µM) upon 
addition of increasing concentration of compounds 
BO3 (left) and BO14 (right) to the [RSA]/[KETO] 
complex. Stoichiometry of the 
[RSA]/[KETO]/[competitor] complexes are: 1/1/0 
(black), 1/1/1 (blue), 1/1/2, 1/1/4,1/1/6, 1/1/8, green 
colour scale, for BO3 and 1/1/0 (black), 1/1/0.5 
(blue), 1/1/1, 1/1/2,1/1/4, 1/1/6, 1/1/8, 1/1/10, green 
colour scale, for BO14. The arrows indicate the 
direction of the shift caused by the increase of 
competitor concentration. 
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Fig. 3.9 Effect on the induced CD spectra of diazepam (DZP, A, B) and ketoprofen (KETO, C) bound 
to RSA (15 µM) upon addition of increasing concentration of rac-ibuprofen (IBU) to the [RSA]/[marker] 
complex. The arrows indicate the direction of the shift caused by the increase of competitor 
concentration. (A) The induced CD signal of the complex [RSA]/[DZP] disappeared completely at 
[IBU]/[DZP] 4:1. (B) A further increase of IBU concentration on the [RSA]/[DZP] complex revealed the 
induced CD spectrum of [IBU]/[RSA] complex at wavelengths below 305 nm. (C) IBU did not show a 
significant displacement of KETO at [IBU]/[KETO] up to 2:1, while higher concentrations of IBU 
caused a significant reduction of CD signal of [RSA]/[KETO] with the contemporary increase of the 
induced CD of [IBU]/[RSA] complex at wavelengths below 305 nm. 
Fig. 3.10 (A) Effect on the induced CD (top) and UV (bottom) spectra of bilirubin (BIL) bound to RSA 
upon addition of increasing concentration of compound BO14 to the [RSA]/[BIL] complex. The arrows 
indicate the direction of the shift caused by the increase of competitor concentration. Stoichiometry of 
the [RSA]/[BIL]/[BO14] complexes:1/1/0, 1/1/0.5, 1/1/1, 1/1/2, 1/1/4, 1/1/6, 1/1/8, 1/1/10. (B) Change in 
the UV signal of bilirubin upon addition of increasing concentration of BO3 and BO14. 
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complex concentration, the induced CD spectrum of the complex RSA/BIL shows a 
change of both intensity and position of the spectrum, probably reflecting the presence 
of multiple stereoselective binding sites. Furthermore the addition of IBU to the complex 
RSA/BIL cause a similar effect on the CD spectrum to those observed with BO3 and 
BO14 [33]. Taking all these information together, the effect of BO3 and BO14 on 
RSA/BIL complex might reflect the direct competition of the two tocainide analogues to 
a secondary stereo-selective binding site of BIL that could be also a binding site for IBU. 
Alternatively, the same effect could be ascribed to an allosteric interaction that affects 
the protein conformation at the bilirubin site level, decreasing its affinity and/or 
modifying the bound conformation. 
 
3.3.5. Tocainide analogues binding location 
From displacement experiments by both affinity chromatography and CD it 
appears clear that the binding site of SAL and PBU, which should be located on 
subdomain IIA of RSA [31] is not a binding site of tocainide analogues. The results 
obtained with the markers of site II and bilirubin site of HSA describe a much more 
complex pattern of interactions between tocainide analogues, profens, diazepam and 
bilirubin on RSA, much different from that of HSA. An attempted model for the binding 
sites of tocainide analogues, ibuprofen, diazepam, ketoprofen and bilirubin that 
summarize the results described in this paper is depicted in Fig. 3.11. None of the 
molecules investigated seems to bind the primary binding site of ibuprofen, not even 
ketoprofen which is known to share the same binding site of ibuprofen on HSA. This 
might be consistent with the opposite stereoselectivity observed for the binding of 
ketoprofen on HSA and RSA [22]. The tocainide analogues could be divided in two 
groups. The binding of one group (BO3, BO5,BO6, BO7, BO10, BO9) showed a higher 
sensitivity to the presence of propanol, a lower binding affinity of ibuprofen (of about 6 × 
103 M−1 as average) for their binding site, an independent binding with ketoprofen, a 
competitive behaviour with diazepam and bilirubin. The other group (BO1, BO2, Toc, 
BO8, BO11, BO12, BO13,BO14) showed a lower sensitivity to the presence of 
propanol, a higher binding affinity of ibuprofen (of about 2 × 104M−1as aver-age) for 
their binding site that matched the affinity of ibuprofen for the diazepam binding site, a 
competitive binding with ketoprofen, a competitive behaviour with diazepam and 
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bilirubin. The higher and lower sensitivity to the presence of propanol could reflect the 
location of the binding site in an area more or less exposed to the solvents. The binding 
of diazepam seems to be affected by tocainide analogues and ibuprofen, thus its 
binding site should occupy a central position with respect the others, but separated from 
ketoprofen binding site. Finally, the effect of ibuprofen and tocainide analogues on the 
induced CD arising from bilirubin bound to the protein might reflect either a 
displacement at a common binding site, or an allosteric effect on the bilirubin affinity 
and/or conformation at the primary binding site of bilirubin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 Conclusions 
 
All the tocainide analogues showed a higher affinity to HSA and RSA than the 
parent compound. Lipophilicity is not the only parameter affecting the binding of these 
molecules to albumins. 
Significant differences in the bound fraction of the analyzed compounds to HSA 
and RSA were observed, being the binding to HSA generally stronger than to RSA. The 
affinity of these compounds to RSA showed characteristic sensitivities to the presence 
Fig. 3.11 Interaction model of compounds BO3, BO14, ibuprofen, diazepam, ketoprofen and bilirubin 
on RSA summarizing the results of this work. The affinity values (KA) measured in this work or found in 
other literature sources are reported. 
a
Value obtained by equilibrium dialysis [31]. 
b
Present work. 
c
Value obtained by circular dichroism [22]. 
d
Value obtained with photolabeled albumins [34]. 
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of small concentration of propanol added to the mobile phase that suggested the 
existence of two main binding families. The higher and lower sensitivity to the presence 
of propanol could reflect the location of the binding site in an area more or less exposed 
to the solvents. HPALC and CD competition experiments confirm a different behaviour 
for the two groups of tocainide analogues. The group presenting higher sensitivity to the 
presence of propanol, showed a lower binding affinity of ibuprofen for their binding site, 
an independent binding with ketoprofen, and a competitive behaviour with diazepam 
and bilirubin. The other group showed a higher binding affinity of ibuprofen for their 
binding site that matched the affinity of ibuprofen for the diazepam binding site, a 
competitive binding with ketoprofen, and a competitive behaviour with diazepam and 
bilirubin. The binding of diazepam seems to be affected by tocainide analogues and 
ibuprofen, thus its binding site should occupy a central position with respect to the 
others, but separated from ketoprofen binding site. 
Drug binding data to albumins from different species are useful to evaluate the 
reliability of extrapolating to human’s distribution data obtained on animals in preclinical 
studies. 
 
Acknowledgements 
This research was supported by the University of Bologna, and MIUR (PRIN 2007 
and 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
References 
 
[1] K.H. Bleicher, H.J. Böhm, K. Mülle, A.I. Alanine, Hit and lead generation: beyond high-throughput 
screening. Nat. Rev. Drug Discov. 2003; 2: 369-378. 
[2] M.P. Gleeson, A. Hersey, D. Montanari, J. Overington, Probing the links between in vitro potency, 
ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 2011; 10: 197-208. 
[3] C. Bertucci, E. Domenici, Reversible and covalent binding of drugs to human serum albumin: 
methodological approaches and physiological relevance. Curr. Med. Chem. 2002; 9: 1463-1481. 
[4] G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano, P. Ascenzi, Human serum albumin: from 
bench to bedside. Mol. Aspects Med. 2012; 33: 209-290. 
[5] T. Peters Jr., All About Albumin: Biochemistry, Genetics and Medical Application, Academic Press, 
New York, 1996. 
[6] Kragh-Hansen U. Structure and ligand binding properties of human serum albumin. Dan. Med. Bull. 
1990; 37:57-84. 
[7] E.M. Vaughan Williams, Classification of antidysrhythmic drugs. Pharmacol. Ther. B 1975; 1: 115-138. 
[8] D.M. Roden, R.L. Woosley, Drug therapy. Tocainide. New Engl. J. Med. 1986; 315: 41-45. 
[9] T.S. Puniani, T.E. Bertorini, Tocainide therapy in muscle cramps and spasms due to neuromuscular 
disease. Muscle Nerve 1991; 14: 280-285. 
[10] C. Franchini, F. Corbo, G. Lentini, G. Bruno, A. Scilimati, V. Tortorella, D. Conte Camerino, A. De 
Luca, Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-
gated Na(+) channels with increased potency and improved use-dependent activity. J. Med. Chem. 2000; 
43: 3792-3798. 
[11] A. De Luca, S. Talon, M. De Bellis, J.F. Desaphy, G. Lentini, F. Corbo, A. Scilimati, C. Franchini, V. 
Tortorella, D. Conte Camerino, Optimal requirements for high affinity and use-dependent block of skeletal 
muscle sodium channel by N-benzyl analogs of tocainide-like compounds. Mol. Pharmacol. 2003; 64: 
932-945. 
[12] A. Catalano, A. Carocci, F. Corbo, C. Franchini, M. Muraglia, A. Scilimati, M. DeBellis, A. De Luca, D. 
Conte Camerino, M.S. Sinicropi, V. Tortorella, Constrained analogues of tocainide as potent skeletal 
muscle sodium channel blockers towards the development of antimyotonic agents. Eur. J. Med.Chem. 
2008; 44: 2535-2540. 
[13] A. Carrieri, M. Muraglia, F. Corbo, C. Pacifico, 2D- and 3D-QSAR of tocainide and mexiletine 
analogues acting as Na(v)1.4 channel blockers. Eur. J. Med. Chem. 2009; 44: 1477-1485. 
[14] M. Muraglia, M. De Bellis, A. Catalano, A. Carocci, C. Franchini, A. Carrieri, C. Fortugno, C. Bertucci, 
J.-F. Desaphy, A. De Luca, D. Conte Camerino, F. Corbo, J.Med. Chem. N-Aryl-2,6-dimethylbenzamides, 
a New Generation of Tocainide Analogues as Blockers of Skeletal Muscle Voltage-Gated Sodium 
Channels. 2014 (submitted for publication). 
[15] M. Pistolozzi, C. Franchini, F. Corbo, M. Muraglia, M. De Giorgi, G. Felix, C. Bertucci, Tocainide 
analogues binding to human serum albumin: a HPLAC and circular dichroism study. J. Pharm. Biomed. 
Anal. 2010; 53: 179-185. 
[16] E. Domenici, C. Bertucci, P. Salvadori, S. Motellier, I.W. Wainer, Immobilized serum albumin: rapid 
HPLC probe of stereoselective protein-binding interactions. Chirality 1990; 2: 263-268. 
[17] D.S. Hage, High-performance affinity chromatography: a powerful tool for studying serum protein 
binding. J. Chromatogr. B 2002; 768: 3-30. 
[18] F. Zsila, Z. Bikàdi, I. Fitos, M. Simonyi, Probing protein binding sites by circular dichroism 
spectroscopy. Curr. Drug Discov. Technol. 2004; 1: 133-153. 
[19] G.A. Ascoli, E. Domenici, C. Bertucci, Drug binding to human serum albumin: abridged review of 
results obtained with high-performance liquid chromatography and circular dichroism. Chirality 2006; 18: 
667-679. 
62 
 
[20] H.S. Kim, I.W. Wainer, Rapid analysis of the interactions between drugs and human serum albumin 
(HSA) using high-performance affinity chromatography (HPAC). J. Chromatogr. B 2008; 870: 22-26. 
[21] G. Ascoli, C. Bertucci, P. Salvadori, Stereospecific and competitive binding of drugs to human serum 
albumin: a difference circular dichroism approach. J. Pharm. Sci. 1995; 84: 737-741. 
[22] M. Pistolozzi, C. Bertucci, Species-dependent stereoselective drug binding to albumin: a circular 
dichroism study. Chirality 2008; 20: 552-558. 
[23] G. Massolini, E. De Lorenzi, M.C. Ponci, G. Caccialanza, Comparison of drug binding sites on rat 
and human serum albumins using immobilized-protein stationary phases as a tool for the selection of 
suitable animal models in pharmacological studies. Boll. Chim. Farm. 1996; 135: 382-386. 
[24] G. Massolini, A.-F. Aubry, A. Mcgann, I.W. Wainer, Determination of the magnitude and 
enantioselectivity of ligand binding to rat and rabbit serum albumins using immobilized-protein high 
performance liquid chromatography stationary phases. Biochem. Pharmacol. 1993; 46: 1285-1293. 
[25] M.N. Martinez, Factors influencing the use and interpretation of animal models in the development of 
parenteral drug delivery systems. AAPS J. 2011; 13: 632-649. 
[26] C. Bertucci, M. Pistolozzi, G. Felix, U.H. Danielson, HSA binding of HIV protease inhibitors: a high-
performance affinity chromatography study. J. Sep. Sci. 2009; 32: 1625-1631. 
[27] J. Yang, D.S. Hage, Role of Binding Capacity versus Binding Strength in the Separation of Chiral 
Compounds by Protein-Based HPLC Columns. J. Chromatogr. A 1996; 725: 273-285. 
[28] T.A.G. Noctor, M.J. Diaz-Perez, I.W. Wainer, Use of a human serum albumin-based stationary phase 
for high-performance liquid chromatography as a tool for the rapid determination of drug-plasma protein 
binding J. Pharm. Sci. 1993; 82: 675-676. 
[29] G.A. Ascoli, C. Bertucci, P. Salvadori, Ligand binding to a human serum albumin stationary phase: 
use of same-drug competition to discriminate pharmacologically relevant interactions. Biomed. 
Chromatogr. 1998; 12: 248-254. 
[30] K.L. Hein, U. Kragh-Hansen, J.P. Morth, M.D. Jeppesen, D. Otzen, J.V. Møller, P.Nissen, 
Crystallographic analysis reveals a unique lidocaine binding site on human serum albumin. J. Struct. Biol. 
2010; 171: 353-360. 
[31] T. Kosa, T. Maruyama, M. Otagiri, Species differences of serum albumins: I. Drug binding sites. 
Pharm. Res. 1997; 14: 1607-1612. 
[32] A.-F. Aubry, N. Markoglou, A. McGann, Comparison of drug binding interactions on human, rat and 
rabbit serum albumin using high-performance displacement chromatography. Comp. Biochem. Physiol. C 
1995; 112: 257-266. 
[33] I. Goncharova, S. Orlov, M. Urbanová, The location of the high- and low-affinity bilirubin-binding sites 
on serum albumin: ligand-competition analysis investigated by circular dichroism. Biophys. Chem. 2013; 
180-181: 55-65. 
[34] K. Kaneko, H. Fukuda, V.T. Chuang, K. Yamasaki, K. Kawahara, H.Nakayama, A. Suenaga, T. 
Maruyama, M. Otagiri, Subdomain IIIA of dog albumin contains a binding site similar to site II of human 
albumin. Drug. Met. Disp. 2008; 36: 81-86. 
[35] I.V. Tetko, J. Gasteiger, R. Todeschini, A. Mauri, D. Livingstone, P. Ertl, V.A.Palyulin, E.V. 
Radchenko, N.S. Zefirov, A.S. Makarenko, V.Y. Tanchuk, V.V.Prokopenko, Virtual computational 
chemistry laboratory--design and description. J. Comput. Aid. Mol. Des. 2005; 19: 453-463. 
[36] A. Goodman, A.G. Gilman (Eds.), The Pharmacological Basis of Therapeutics,ninth ed., Mc Graw-
Hill, New York, 1996. 
 
 
 
 
 
 
 
63 
 
 
 
 
 
 
 
Chapter 4 
Optical biosensor analysis in studying new 
synthesized bicalutamide analogues binding to 
androgen receptor 
Cecilia Fortugno, G. Varchi, A. Guerrini, P.A. Carrupt, C.Bertucci 
 
Journal of Pharmaceutical and Biomedical Analysis, accepted for 
publication. 
 
 
 
 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
Abstract 
 
Bicalutamide (Casodex®) is a non-steroidal anti-androgen drug used in the 
treatment of prostate cancer, which represents the second most common malignancy 
diagnosed in men worldwide. In this work, we analyze the ability of some novel 
bicalutamide analogues to bind the androgen receptor, by using an optical biosensor. 
Androgen receptor was covalently immobilized on a carboxy methyl dextran matrix.  
The immobilized receptor chip was then used for the binding experiments of the 
bicalutamide analogues. The (R)-bicalutamide dissociation constant was in good 
agreement to the value reported in literature obtained by using radiolabeled targets. 
Most of the new synthesized compounds showed higher androgen receptor binding 
level, when compared to the reference. Our results clearly indicate that the surface 
plasmon resonance (SPR) technique offers many advantages with respect to other 
available technologies in terms of studying biomolecular interactions. Moreover, this 
study provides an effective methodology for determining the binding affinity of novel 
chemical entities for the isolated androgen receptor, thus excluding possible off-target 
interactions occurring in conventional cell-based techniques.  
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4.1 Introduction  
 
The study of the biorecognition phenomena represents a fundamental step of the 
early phases of drug discovery and development, for both characterizing new potential 
targets and identifying new lead candidates.  
A wide variety of analytical, affinity based and spectroscopy, techniques are 
available to define the binding parameters of interacting molecules, as well as to 
determine the structural features driving the process [1-7]. However, most of them 
require high amounts of compounds [2,3] or the use of target molecules labeled with a 
fluorescent [5] or radioactive tag [8].  
Among all the available analytical techniques, surface plasmon resonance (SPR) 
biosensor technology has been recognized as a powerful tool for drug discovery and 
development applications giving a great improvement to the biomolecular interaction 
analysis field [9-14].  
Real time and label-free assay are the main advantages of the SPR technique. 
Biosensor experiments involve the immobilization of one reactant on the biosensor 
surface and the monitoring of its interaction with a second component in solution. The 
instrument measures the change in the refractive index that occurs during complex 
association (or dissociation) close to the surface [15]. This real time analysis allows the 
determination of  (i) the amount of bound analyte, (ii) its affinity for the receptor and (iii) 
the kinetic rates of the interaction (kon and koff) [16]. The response obtained is directly 
proportional to the mass of the analyte, which binds to the surface. In the past, this has 
limited standard SPR analyses to the study of analytes with molecular masses of 
several thousand daltons. Nowadays considerable improvements have been introduced 
in this technique in terms of hardware, experimental design and data processing, thus 
also low molecular weights compounds can be monitored by using the optical biosensor 
technique [17].  
In this paper we describe the use of current SPR technology for characterizing the 
binding process between the androgen receptor (AR) and nine novel synthetic AR 
ligands (400-600 Da).  
The AR is a member of the steroid receptor superfamily and its ligands play 
important roles in several biological processes such as the development and 
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maintenance of secondary sexual organs, bone, muscle, and others [18,19]. However, it 
has been widely demonstrated that approximately 90% of prostate cancers (PCa) are 
dependent on androgens at initial stages and that AR is expressed throughout cancer 
progression. Endocrine therapy of PCa is directed towards the reduction of serum 
androgens and/or the AR inhibition with anti-androgens. The latter occurs by 
competitively blocking the interaction between the AR and the endogenous ligands. 
Among the AR antagonists, non-steroidal antiandrogen (R,S)-bicalutamide (Casodex®, 
1), has been chosen as the routine clinical treatment due to its superior pharmacokinetic 
profile and minor side-effects [20]. Nevertheless, after its long-term use, a subset of 
patients benefit of the anti-androgen discontinuation (anti-androgen withdrawal 
syndrome, AWS), indicating that these drugs serve as agonist under resistance 
circumstances [21]. Indeed, there is an urgent need to find novel and more active non-
steroidal antiandrogens with superior affinity for the receptor and able to act on resistant 
PCa stages.  
 In this work the amine-coupling procedure was used to covalently immobilize the 
AR on a carboxy methyl dextran matrix. The immobilized receptor chip was then used to 
determine and compare the binding properties of (R)-bicalutamide (the most active 
enantiomer) and of the novel synthesized derivatives (Fig. 4.1) [22-25]. The androgen 
receptor binding level of all the analogues under investigation was ranked, allowing the 
identification of the higher bounded compounds, compared to the reference, e.g. (R)-
bicalutamide, which is the active enantiomer of the commercial drug [26]. Kinetic 
binding studies of (R)-bicalutamide and some of the analogues were carried out using 
single cycle and multi cycle kinetics approaches. Moreover, the reliability of the binding 
parameters obtained was verified by repeating the experiments over time. 
 
4.2 Materials and methods   
 
4.2.1 Chemicals  
Compounds (R)-bicalutamide, (S)-BIC14, (S)-BIC20, (R)-BIC33, (S)-BIC32, (R)-
BIC30, (R)-BIC51, (R)-BIC59 were prepared as previously reported [22-25]. BIC60 
synthesis was performed according to reported procedure [22]. BIC60 characterization 
1HNMR (400 MHz, C6D6) δ:9.31 (s, 1H, NH), 7.56-7.50 (m, 3H, ArH), 6.97 (d, J=2.0Hz, 
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1H, ArH), 6.88-6.85 (m, 2H, ArH), 6.78 (d, J=8.4Hz, 1H, ArH), 6.60 (t, J=8.4Hz, 2H, 
ArH), 6.43 (t, J=8.4Hz, 2H, ArH), 4.18 (d, J=14Hz, 1H, CH2), 3.12 (d, J=14.4Hz, 1H, 
CH2), 2.27 (bs, 2H, NH2); 13CNMR (100 MHz, C6D6) δ: 170.6, 165.5 (d, J=305.7), 
163.0 (d, J=298Hz), 141.1, 136.8, 135.5, 130.8, 130.7, 127.1, 127.0, 121.3, 116.8 (q, 
J=4.7Hz), 116.4, 116.2, 115.9, 115.7, 115.4, 104.9, 64.3, 62.0.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Androgen Receptor (recombinant, expressed in insect cells) was purchased from 
Sigma-Aldrich (Swiss) at a concentration of 0.1 mg/mL in 20 mM Tris-Cl (pH 8.0), 20% 
Glycerol, 100 mM KCl, 1 mM DTT and 0.2 mM EDTA. Monosodium phosphate 
(NaH2PO4 x 2H2O) was purchased from Merck (Darmstadt, Germany). Sodium chloride, 
potassium chloride, Tween-20 and N-(2-hydroxyethyl)-piperazine-N’-(2-ethanesulfonic 
Fig. 4.1 Structures of (R)-bicalutamide and its analogues. 
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acid) (HEPES) were from Sigma–Aldrich (Buchs, Switzerland). Sodium acetate and 
sodium hydroxide were from Fluka (Buchs, Switzerland). Dimethyl sulfoxide (DMSO) 
was purchased from Fisher Scientific (Switzerland). 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), 
ethanolamine-HCl, HBS-P+ (0.1 M HEPES, 1.5 M NaCl and 0.5% v/v Surfactant P20) 
and the sensor chip with carboxymethylated matrix CM5 were from Biacore (GE 
Healthcare). Twice distilled and degassed water deionized and filtered with Millipore Elix 
3 was used for mobile phase’s preparation. The buffer solutions were filtered through a 
0.45-µm membrane filter and degassed before use. 
 
4.2.2 Instrumentation 
Surface plasmon resonance analyses were performed by using Biacore X100 
optical biosensor, thermostated at 25°C and equipped with research-grade CM5 sensor 
chips (Biacore). The Biacore X100 evaluation software was used for evaluation of 
sensorgrams. 
Biosensor data were analyzed using Biacore™ X100 2.0 Evaluation Software. 
Data processing was performed in BIA evaluation software. 
 
4.2.3 Androgen receptor immobilization 
The androgen receptor surface was prepared by using standard amine-coupling 
procedure [27]. The androgen receptor was coupled through his surface amine groups 
via amine bonds with the CM5 sensor chip of the Biacore X100 instrument. The running 
buffer was PBS (Phosphate buffered saline: 20 mM phosphate buffer, 137 mM sodium 
chloride, 2.7 mM potassium chloride, 0.005% Tween-20, pH 7.4) and the temperature 
was set at 25 °C. The receptor was dissolved at 50 μg/mL in 10 mM Sodium Acetate pH 
4.0. Carboxyl groups on the dextran layer of the chip were activated by injecting a 1:1 
mixture of 0.4 M N-ethyl-N-(3-dimethylaminopropyl) carbodiimide and 0.1 M N-
hydroxysuccinimide for 10 min at a flow rate of 5 μL/min. The androgen receptor 
solution was injected in channel 2 and was allowed to react for 7 min at a flow rate of 5 
μL/min. The remaining carboxyl groups were blocked by injecting a solution 1 M 
ethanolamine for 7 min at a flow rate of 5 μL/min. The entire coupling procedure results 
in 8109 RU of androgen receptor immobilized. The receptor was immobilized only in 
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one channel of the sensor chip in order to monitor the possible non-specific bindings by 
means of the second channel. The reference control channel was only activated with 
1:1 EDC/NHS mixture, and then treated with ethanolamine to block NHS-ester groups. 
The androgen receptor immobilization experiment is summarized in the sensorgram 
shown in Fig. 4.2, where the optical biosensor response (resonance units) is reported 
as a function of time. After the immobilization the sensor chip surface was stabilized by 
various injections of running buffer at 30 μL/min all over the night. 
The sensor chip was stored in a refrigerator, in a 50 ml tube containing running 
buffer without DMSO (see section 4.2.5) so that the support was completely covered. 
 
4.2.4 Preparation of sample solutions 
All the set of analyzed compounds were stored as 1mg/mL stock solutions in 
100% dimethyl sulfoxide (DMSO) and diluted to 1 mM with 100% DMSO. Immediately 
prior to analysis, samples were mixed with assay buffer and DMSO providing a 10 μM 
compound in a final buffer composition of 10 mM Hepes, 150 mM sodium chloride, pH 7 
and 2% (v/v) DMSO, which was also used as the instrument running buffer and sample 
dilution buffer. The running buffer should contain the same DMSO concentration as the 
samples, since DMSO has a high refractive index contribution and small differences in 
DMSO concentration will significantly affect the bulk response. 
 
4.2.5 Ranking of ligand binding to Androgen Receptor 
The running buffer for AR ranking analysis consisted of 10 mM Hepes, 150 mM 
sodium chloride, DMSO 2% (v/v), pH 7. In the ranking format 10 μM of the compounds 
under investigation were injected at a flow rate of 10 μL/min over the AR surface at 25 
°C. Ligands were allowed to associate with the receptor for 60 s and dissociation was 
monitored for 4 min. Surface regeneration was obtained by injecting two short pulse of 
HBS 100 mM for 30 s at a flow rate of 30 μL/min and flushing running buffer at 5 μL/min 
for some min before each injection. Since the dissociation of all ligate rarely occurs and 
the repeated cycles of analysis need to start with the biosensor surface free of residual 
material, the regeneration conditions are very important for experiment success. A 
buffer injection between every sample cycle was included in order to check the possible 
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carry-over of analyte to the next cycle, and to stabilize the surface. All samples were 
injected in duplicate. 
 
4.2.6 Kinetic Analysis of Androgen Receptor/Ligand interactions 
Kinetic studies were carried out with the following compounds: (R)-bicalutamide, 
(S)-BIC32 and (R)-BIC33. Kinetic and equilibrium constants were determined by 
injecting a wide range of ligate concentrations (approximately from 1 μM to 20 μM) at a 
flow rate of 30 μl/min over the androgen receptor chip at 25°C. The concentration range 
was chosen on the basis of the linearity of the SPR responses obtained: when 
concentrations below 1 μM were used the SPR signals were not detectable; on the 
other hand concentrations above 20 μM led to artifacts, due to crowding of interacting 
molecules on the surface as well as to precipitation of poor soluble compounds. 
Buffer blanks were injected periodically and all sensorgrams were processed by 
using double referencing: the responses from the Fc1 channel control were firstly 
subtracted from the binding responses collected over the reaction surfaces and then the 
response from an average of the blank injections was also subtracted. Binding of each 
sample was allowed to occur for 60 s and the dissociation phases were of 180 s. The 
androgen receptor surface was regenerated between binding cycles with two short 
pulses of HBS 100 mM for 30 s. Kinetic experiments with (R)-bicalutamide and (S)-
BIC32 were set up using the kinetic wizard in Biacore X100 evaluation software with the 
single-cycle approach; whereas the kinetic analysis of (R)-BIC33 were performed using 
multi-cycle approach. The kinetic fitting was carried out using 1:1 Langmuir binding 
model. The equilibrium dissociation constant (KD) was obtained by the ratio of the 
binding on (kon) and off (koff) rate (KD = koff/kon). Chi-square value (χ2) is used as a 
statistical measure to judge how closely the model given by the software fits with the 
experimental data. The DMSO calibration plot was built prior to perform each kinetic 
analysis. The complete kinetic analysis was performed three times over the same chip. 
 
4.2.7 Solvent Refractive Index correction 
A solvent refractive index (RI) correction procedure was included in the assay 
protocols to avoid variations in the bulk response between samples. As DMSO has a 
high refractive index, small variations in DMSO concentration between sample solutions 
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and running buffer often lead to significant nonspecific signals. The solvent RI correction 
becomes essential when working with low molecular weight compounds that give 
intrinsically small responses. In fact, in this case variations in the bulk RI can be of the 
same order of magnitude as the responses expected from the binding interaction. A 
series of eight buffer solutions containing concentrations of DMSO (1.5-2.8 %) were 
injected in sequence over reference and AR surfaces. The difference in response 
between AR and reference flow cells plotted as a function of the response in the 
reference flow cell provides us the DMSO calibration plot [28]. All the response levels 
obtained during the analysis were corrected with this curve. 
 
4.3 Results and discussion 
 
SPR biosensor technique has been used for nuclear receptor binding assays, as 
screening tool for identifying active compounds and to get information on the 
mechanism of the receptor mediated activity [29-32]. In the case of androgen receptor, 
the KD of (R)-bicalutamide has been obtained by displacement measurements of a 
labeled marker compound in a cell culture [26]. 
The use of an isolated receptor can represent a valuable methodology for 
medium-high throughput screening of the binding properties of active compounds. 
 
4.3.1 Androgen receptor immobilization 
The most challenging step when setting up SPR experiments is immobilizing the 
target protein to the sensor surface without modifying its activity. Immobilization can 
either be direct, by covalent coupling the target protein, or indirect, through its capture 
by a molecule with high affinity for the target protein itself and covalently bounded to the 
sensor surface. Choosing the right immobilization strategy is not a simple issue, and 
several aspects should be taken into account. In particular, the orientation of the 
immobilized receptor, the local surface environment, the linkage stability, and the 
possible effects of the coupling chemistry on components of the system, represent 
critical aspects of the chosen strategy [16]. 
It has been already demonstrated that bicalutamide and its analogues bind 
androgen receptor ligand binding domain (LBD), which is located in the C-terminal 
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domain of the receptor [33]. The amine coupling method was used (see section 4.2.3) to 
immobilize the AR on the chip surface. In order to determine suitable coupling 
conditions, a pre-concentration test of the ligand on the surface was done. Since the 
receptor had an isoelectric point of 6.3 [34], we decided to use ligand solutions in 
different coupling buffers, covering the pH range 4-5 in steps of 0.5 pH units. In fact, it is 
already known that the immobilization buffer pH value should be at least 0.5-1 unit 
below the isoelectric point of the ligands and higher than 3.5, so that the surface and the 
ligand carry opposite net charges. The condition that gave adequate electrostatic pre-
concentration of ligand to the dextran matrix was the use of buffer at pH 4. 
The entire coupling procedure results in 8109 RU of androgen receptor 
immobilized. The immobilization experiment is summarized in the sensorgram shown in 
Fig. 4.2. The reference channel was treated as the experiment channel in order to follow 
nonspecific binding phenomena which could take place on the biosensor surface. The 
binding of (R)-bicalutamide was used to check that LBD was not involved in the 
immobilization process. As a result the KD of the reference compound was in agreement 
to that reported in the literature [26]. The immobilized AR was stable over four weeks as 
demonstrated by the consistent ranking obtained from analyses carried out at different 
times for the same set of ligate concentrations. 
 
4.3.2 Ranking analyses 
Bicalutamide and its analogues were floated over the AR covalently immobilized 
chip. The ranking of the analytes under investigation for their AR binding level was 
performed by simply measuring the degree of binding at only one concentration value. 
The screening was performed at 10 μM. This concentration was low enough to minimize 
sample consumption and allow analysis of poorly soluble compounds, but also high 
enough to give a reasonable signal. The maximum binding response after a 60 s 
injection was determined for each compound. As the binding response in a Biacore 
assay is a function of the total molecular mass close to the chip surface, binding data 
were adjusted for the molecular weight of each drug in order to give comparable molar 
values. All the bicalutamide analogues showed a higher androgen affinity when 
compared to the reference, e.g. (R)-bicalutamide, with the exception of the (S)-BIC14 
that shows a lower affinity (Fig. 4.3). The increasing of lipophilicity of the substituent at 
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the chiral stereocenter also increases the affinity of these compounds to AR. This 
behavior matches with the calculated log P of the compounds under investigation (see 
Table 4.1). In fact, (R)-bicalutamide and (S)-BIC14 show a lower predicted logP than 
the other compounds. On the other hand, (R)-BIC51, (R)-BIC59 and (S)-BIC32 hold the 
highest predicted log P value and produce the highest receptor binding affinity. 
Moreover, comparing the results of Fig. 4.3 and Table 4.1, we can appreciate that the 
ranking of the compounds based on the binding level reflects those based on the log P 
parameter, with the only exception of (R)-BIC30. These data indicate that 
hydrophobicity is also an important parameter in determining the interaction between 
the analyzed molecules and AR. In particular, the presence of two aromatic rings on the 
chiral center determines the increase of lipophilicity but also a better accommodation 
into the receptor pocket(s) with increased affinity. 
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Fig. 4.2 Sensorgram of the Androgen receptor immobilization to the carboxymethyl dextran matrix: (1) 
buffer baseline stabilization; (2) EDC/NHS mixture add; (3) buffer re-equilibration; (4) Androgen receptor 
in acetate buffer add (7 minutes of reaction); (5) buffer washes; (6) block of non-coupled activated CMD 
sites with ethanolamine (7 min of reaction); (7) baseline stabilization. 
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It’s also interesting to note that (R)-BIC60 showed higher affinity to AR than the 
corresponding racemate (rac-BIC60), confirming the significant influence of the 
stereochemistry on the binding ability, as observed for (R)- and (S)-bicalutamide [26]. 
These data prove that this technique provides also structure-activity relationship 
information useful for future rational design of potential new drugs in the treatment of 
androgen receptor related diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.3 Kinetic analyses 
A detailed kinetic analysis was performed for the following compounds: (R)-
bicalutamide, (S)-BIC32 and (R)-BIC33. The binding responses obtained for  
concentration series of each of these compounds injected over the AR surface are 
reported in the Fig. 4.4. The real time detection allows to obtain kinetic rate constants of 
the interaction (association and dissociation rate constants) by analyzing the 
sensorgram shape using a mathematical model for the interaction mechanism. Each of 
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Figure 4.3 Ranking analyses of bicalutamide analogues performed at a concentration of 10 μM in 
HBS 10 mM + NaCl 150 mM + 2% DMSO, pH7. Binding data were adjusted for the molecular weights 
of each compounds, in order to give comparable molar values. 
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the analyzed interaction was well described by a 1:1 interaction model (Fig. 4.4). This 
model can be described by the following equation: 
 
 
 
 
where kon is the association rate constant (M
-1s-1) and koff is the dissociation rate 
constant (s-1). The equilibrium dissociation constants can be derived directly from the 
ratio of the rate constants obtained (KD = koff/kon). 
The (R)-bicalutamide and (S)-BIC32 kinetic experiments were set up using the 
kinetic wizard on Biacore X100 with the single-cycle approach (see Fig. 4.4a, 4.4b); 
whereas the (R)-BIC33 kinetic analyses were performed using multicycle approach (see 
Fig. 4.4c). In both cases several analyte concentrations were injected over the surface 
to determine the binding data. Multicycle kinetics runs each analyte concentration in a 
separate cycle, and the surface is regenerated between each cycle. On the contrary, in 
Sample miLog Pa
(S)-bic14 2.197
(R)-bicalutamide 2.154
(R)-bic33 3.416
(R)-bic30 4.477
(rac)-bic60 3.579
(R)-bic60 3.579
(S)-bic20 3.928
(S)-bic32 4.512
(R)-bic59 4.552
(R)-bic51 4.765
Table 4.1 Predicted log P values of the 
compounds under investigation. Compounds 
are tabulated according to the ascending 
degree of binding for the AR. 
a
Calculated using online 
www.molinspiration.com/cgi-bin/properties site 
(Molinspiration Property Engine v2009.01) 
A + B ⇌ AB
kon
koff
77 
 
the single cycle experiment, different concentrations of the analyte are injected in one 
cycle without regeneration between sample injections. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Analysis of the data revealed that (R)-bicalutamide binds to the AR with an 
association rate constant of 371.4 M-1s-1 and a dissociation rate constant of 2.63 × 10-5 
s-1, resulting in a KD of 70.7 nM. This value is in good agreement with the KD value of 
11 Nm reported in literature for the same interaction obtained by using radiolabeled 
marker in cell cultures [26]. The R-bicalutamide KD evaluation was also repeated at 
different moments of the sensor chip’s life, following always the same protocol: the 
values obtained represent an evidence of the reproducibility of the employed method 
(37.4 nM and 43.3 nM). 
The same analysis was performed with the novel synthetic derivatives. Significant 
differences were found for both association (kon) and dissociation rates (koff) (Table 4.2). 
Despite being the compound with lower affinity among those analyzed, (R)-bicalutamide 
presents the slowest association rate constant and the faster dissociation rate constant. 
Out of all, (R)-BIC33 exhibited the most rapid association rate constant, almost 80-fold 
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Fig. 4.4 Kinetic profiles for (R)-bicalutamide (A), (R)-BIC32 (B) and (R)-BIC33 (C) binding to AR 
determined using single cycle (A, B) and multi-cycle (C) kinetics. Sensorgrams show blank and 
reference subtracted data with kinetic fit for 1:1 interaction model overlaid in black. 
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higher than the reference kon, although it did not display a high affinity for the receptor in 
the ranking analysis (Fig.3). The dissociation rate constants observed for (S)-BIC32 was 
149-fold slower than the reference, respectively. All these considerations should be 
taken into account during lead optimization studies. In fact, using just the affinity value 
as the ideal parameter for biological activity considerations could cancel important 
information about the relationship between activity and structure of new synthesized 
compounds [35]. At this stage of drug development, the best would be to consider both 
the kinetic parameters, in order to obtain a clear overview of how strong the recognition 
process (kon) is and how stable the complex between the binders (koff) is. 
The equilibrium dissociation constant (KD) showed that (S)-BIC32 had an higher 
affinity for the receptor than the lead compound (173 pM).This datum was in 
accordance with the ranking study presented before. 
 
 
 
 
 
 
 
 
 
 
 
 
4.4 Conclusions 
 
SPR based optical biosensors offers some advantages with respect to other 
spectroscopic and affinity based techniques. In fact, the drug/protein binding process is 
monitored in real time with the SPR based biosensor, allowing the evaluation of the 
kinetics parameters directly from the shape of the sensorgrams recorded. Furthermore, 
this technique requires small amounts of both the ligand and the ligate, and it is well 
suited for medium-high throughput screening applications. 
SAMPLE kon (M
-1 s-1) koff (s
-1) KD (M)
(R)-bicalutamide 371.4 2.63 x 10-5 7.07 x 10-8 a
(S)-bic32 1024 1.77 x 10-7 1.73 x 10-10
(R)-bic33 2.77 x 104 n.d.b n.d.b
Table 4.2 Rate constants and affinities of AR/ligand interactions. Parameters were estimated by global 
fit of an equation describing 1:1 binding. 
a
value in good agreement with those reported in literature obtained by usingradiolabeled target [26] 
b
not determined, because outside of instrument range 
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In particular, the present study reports on the determination of the binding affinity 
and the kinetics parameters of the series of novel androgen receptor ligands. Our data 
indicate that this methodology can represent a very useful and reliable alternative to 
conventional assays based on displacement methodology with labeled markers in cell 
cultures. Moreover, when the proper protein-sensor conjugation set up is established, 
SPR can provide good approximation data of binding affinity between novel chemical 
entities and the isolated androgen receptor. These data might deliver important 
information during drug discovery and development steps, because they will account for 
the sole AR binding pocket-ligand affinity, purged from “off-target” interactions, which 
are likely to occur in all the conventional cell-based techniques. 
In our work we demonstrated that the KD value of the reference compound, e.g. 
(R)-bicalutamide, bound to the AR is in good agreement with the KD value reported in 
literature for the same interaction obtained by using radiolabeled target [26]. This result 
confirmed that the AR was properly immobilized on the biosensor surface and that the 
assay could be reliable applied to the other compounds. Significant differences were 
found for both association (kon) and dissociation rates (koff) between all compounds 
under investigation. Overall, (R)-BIC33 exhibited the highest association rate constant, 
almost 80-fold higher than the reference, but it did not show high affinity for the 
receptor. The dissociation rate constant observed for (S)-BIC32 was 149-fold slower 
than the reference compound. 
In order to obtain a clear overview of how strong the recognition process (kon) is 
and how stable the complex between the binders (koff) is, we believe that both 
thermodynamic and kinetics data should be taken into account during lead optimization 
studies. 
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Chapter 5 
Bicalutamide analogues interaction with human 
serum albumin and rat serum albumin: an affinity 
chromatography and circular dichroism 
investigation 
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Abstract 
 
In this work the binding of some novel bicalutamide analogues (see section 4.1) 
for the main plasma protein, serum albumin, was characterized by using high 
performance affinity chromatography (HPALC) and circular dichroism (CD). The study 
was carried out with two different serum albumins, Human Serum Albumin (HSA) and 
Rat Serum Albumin (RSA), in order to underline the possible differences among species 
when performing pharmacokinetic studies. Concerning HPALC investigation, HSA was 
immobilized on a silica HPLC column, through the reported online procedure, allowing 
the binding properties of the protein to be maintained. With the HSA column the ranking 
of the bicalutamide analogues for their HSA bound fraction was performed, by 
measuring the degree of binding at only one concentration value. CD displacement 
experiments were carried out to characterize the high affinity binding sites of these 
compounds to the two plasma proteins, HSA and RSA. The change of the induced CD 
spectra observed for a protein:marker complex in the presence of increasing 
concentrations of the lead compound was monitored. 
All the compounds under investigation showed high affinity to HSA. Competition 
experiments revealed an independent binding at benzodiazepine site and site II for 
RSA. An independent binding at site II and a cooperative binding at the bilirubin site 
was observed for HSA. 
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5.1 Experimental 
 
5.1.1 Chemicals 
Human serum albumin (HSA, essentially fatty acid free, A1887),rat serum albumin 
(RSA, essentially fatty acid and globulin free, A6414), 1-propanol, Dimethyl sulfoxide 
(DMSO),  L-tryptophan (L-Trp), N-benzoyl-dl-leucine, S-warfarin, rac-ibuprofen (IBU), 
rac-ketoprofen (KETO), rac-suprofen, rac-indoprofen and bromophenol-blue were 
purchased from Sigma–Aldrich (Milan, Italy). Diazepam (DZP) was kindly provided by 
Professor Regina H. Costa Queiroz, Faculty of Pharmacy, University of San Paolo, at 
Ribeirao Preto (Brazil). Clonazepam, temazepam and lorazepam were kindly provided 
by Prof. Lucacchini, University of Pisa (Italy). KH2PO4, K2HPO4, and (NH4)2SO4 
powders were purchased from Carlo Erba (Milan, Italy). Potassium phosphate buffers 
(PB) were prepared by adjusting the pH of solutions of K2HPO4 with equimolar solutions 
of KH2PO4. Twice distilled and degassed water deionized and filtered with a MILLI-
RX20 (Millipore) system was used for mobile phase’s preparation.  
 
5.1.2 Bicalutamide analogues, synthesis  
Compounds (R)-bicalutamide, (S)-BIC14, (S)-BIC20, (R)-BIC33, (S)-BIC32, (R)- 
BIC30, (R)-BIC51, (R)-BIC59 were prepared as previously reported [1-4]. BIC60 
synthesis was performed according to reported procedure [1]. BIC60 characterization 
1HNMR (400 MHz, C6D6) δ:9.31 (s, 1H, NH), 7.56-7.50 (m, 3H, ArH), 6.97 (d, 
J=2.0Hz, 1H, ArH), 6.88-6.85 (m, 2H, ArH), 6.78 (d, J=8.4Hz, 1H, ArH), 6.60 (t, 
J=8.4Hz, 2H, ArH), 6.43 (t, J=8.4Hz, 2H, ArH), 4.18 (d, J=14Hz, 1H, CH2), 3.12 (d, 
J=14.4Hz, 1H, CH2), 2.27 (bs, 2H, NH2); 13CNMR (100 MHz, C6D6) δ: 170.6, 165.5 
(d, J=305.7), 163.0 (d, J=298Hz), 141.1, 136.8, 135.5, 130.8, 130.7, 127.1, 127.0, 
121.3, 116.8 (q, J=4.7Hz), 116.4, 116.2, 115.9, 115.7, 115.4, 104.9, 64.3, 62.0. The 
structures of the compounds are reported in Fig.5.1. 
 
5.1.3 Instruments 
The HPLC apparatus consisted of a Jasco PU-2089 plus (Jasco, Tokyo) HPLC 
pump, a Rheodyne injector system with a 20 µL loop and a Jasco MD-2010 plus (Jasco,  
Tokyo) diode array detector. The column was thermostated at 28°C with a Column 
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Chiller Model 7955 (Jones Chromatography Ltd., UK). Buffers were filtered through 0.22 
µm mixed cellulose esters filter membranes (Milli-pore, Milan, Italy). The mobile phases 
were degassed prior to use by ultrasonic waves for at least 15 min. 
CD measurements were performed with a Jasco J-810 spectropolarimeter (Jasco, 
Tokyo, Japan) equipped with a Peltier type temperature control system set at 25°C. The 
spectra were recorded using 1 cm pathlength cell at a scan rate of 20 nm/min, time 
constant 2 s, resolution 0.2 nm, and spectral bandwidth 1 nm. 
Fig. 5.1 Structures of (R)-bicalutamide and its analogues. 
(S)-BIC14 (S)-BIC20 (R)-BIC30
(S)-BIC32 (R)-BIC33
(R)-BIC51
(R)-BIC35
(R)-BIC52 (R)-BIC59
rac-BIC60 (R)-BIC63
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5.1.4 Column preparation 
The silica monolithic column (50 mm × 4.6 mm i.d.), 20 nm mesopores, were 
silanized by an in situ process as previously reported [5], with slight modification. 
HSA was covalently immobilized online on the monolithic epoxy-silica columns 
following a previously reported procedure [6]. In brief, HSA solution (10 mg/mL of 
protein in PB 50 mM, pH 6.5, 1 M ammonium sulphate) was circulated through the 
epoxy-silica column in closed circuit for 24 h. The column was washed with 120 mL of 
PB (50 mM, pH 7.4), and 100 mL of 1 M glycine dissolved in PB (50 mM, pH 7.4). The 
column was then washed with PB (67 mM, pH 7.4)/1-propanol 95:5 and stored at 4°C 
until use. The HSA-based column was employed for the determination of the bound 
fractions of the compounds under investigation. 
 
5.1.5 Column characterization 
The HSA-based column was characterized in terms of amount of albumin correctly 
immobilized by the frontal analysis of L-tryptophan as previously reported [6,7]. A series 
of solutions of L-trp in PB (67 mM, pH 7.4) ranging from 5 µM to 60 µM were 
continuously applied to the column as mobile phases. The relevant breakthrough 
volume (V −V0) of each solution, where V is the breakthrough volume and V0 is the 
system void volume, was determined and the following linear equation was applied [7]: 
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(see section 3.2.6). 
A series of racemates reported to bind the proteins in a stereoselective manner 
(rac-warfarin, rac-indoprofene, rac-ketoprofen, rac-suprofen and rac-ibuprofen) were 
used to check the dependability of the albumin-based column. Stock solutions of the 
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racemates prepared 1 mg/mL in 1-propanol were diluted with PB (67 mM, pH7.4) and 
injected into the columns at the final concentration of 60 µM. Mobile phases were 
mixtures of PB (67 mM, pH 7.4)/1-propanol. 
 
5.1.6 Bound fraction determination 
For all samples a stock solution at a concentration of 0.5 mg/ml in DMSO was 
prepared, and diluted with the 67 mM phosphate buffer at pH 7.4 just before injection. 
The concentration of working solutions was 20 µM. The chromatographic retention was 
reported as the capacity factor (k’) and its logarithm (log k’), where k’ is defined as 
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(tdrug= retention of the solute; t0= retention of an unretained solute). Samples were 
analyzed in duplicate. The flow was set at 1 mL/min. The k’ values were determined in 
absence or presence of 1-propanol, added to the mobile phase at several 
concentrations. Mobile phases were composed of PB (67 mM, pH7.4)/1-propanol 
ranging from 90:10 to 100:0. Because of the low solubility of some compounds, not all 
compounds have been tested without 1-propanol in the mobile phase. The retention 
values were plotted as log k versus the organic modifier concentration. The bound drug 
fraction (B%) was determined as the measured capacity factor k’, according to a 
previously published method [8]. 
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5.1.7 Circular dichroism: displacement experiments 
The displacement experiments were carried out using rac-bicalutamide as the 
competitor. Diazepam (DZP) and rac-ketoprofen (KETO) were used as selected 
markers for benzodiazepines binding site and Site II, respectively; bromophenol-blue 
(BPB) as markers for bilirubin binding site. The change in the CD signal after addition of 
different amounts of rac-bicalutamide to a solution containing equimolar concentrations 
of HSA or RSA and marker [15 µM in PB (pH 7.4; 67 mM)] were monitored. Stock 
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solutions of rac-bicalutamide (15 mM in 1-propanol), DZP (15 mM in 1-propanol), KETO 
(15 mM in 1-propanol), BPB (15 mM in 1-propanol), HSA and RSA (150 µM in PB, pH 
7.4, 67 mM) were prepared immediately before the experiments. All the measurements 
were carried out using a 10 mm path length cell. The working solutions were prepared 
by mixing the protein under investigation, marker and displacers at molar ratios from 
1:1:0 up to 1:1:8. 
 
5.2 Results and discussion 
 
5.2.1 Column characterization 
The HSA-column was characterized by frontal analysis in order to determine the 
amount of protein immobilized onto the column (Fig.5.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The plot of the bound analyte versus the reciprocal of its concentration (see 
Section 3.2.4) was used to determine the amount of albumin correctly anchored to the 
silica matrix and the affinity constant of the analyte for the albumin (Fig. 5.3). L-Trp 
showed to bind to a single site on albumin (r2= 0.9993) with a KA of 1.25 × 10
4 M−1, in 
good agreement with the value of 1 × 104 M−1 reported in the literature [9]. The amount  
of immobilized albumin was 11.97 mg, thus considering an amount of silica of about 
Fig. 5.2 Acquisition curves obtained by frontal analysis. 
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0.25 g per column the amount of protein immobilized resulted in about 48 mg/g silica. 
By injecting racemates of drugs or amino acids reported to bind the protein in an 
enantioselective manner we also checked that the immobilization procedure preserved 
the native binding properties of the proteins. We chose N-benzoyl-DL-leucine, different 
benzodiazepines (temazepam, lorazepam and clonazepam) and various aryl-propionic 
acids (rac-ketoprofen, rac-ibuprofen, rac-indoprofen and rac-suprofen), which are 
known to bind to Site II on the HSA, as well as rac-warfarin, known to bind to Site I on 
the albumin. The enantioresolution was obtained for all the analyzed racemates. 
Moreover most of the enantiomers analyzed have also shown selectivity values (α= 
kB/kA) higher than 1.5, demonstrating the excellent quality of this column (see Fig. 5.4). 
 
5.3.2 Bound fraction determination 
Bicalutamide and its analogues were injected into the HSA covalently immobilized 
column. The ranking of the bicalutamide analogues for their HSA bond fraction was 
performed on the basis of the capacity factor, k. The analyses were carried out 
gradually decreasing the propanol concentration in the mobile phase. Because of the 
Fig. 5.3 Frontal analysis plot: mHSA and KA evaluation. 
 
y = 0,4443x + 5,5498
R² = 0,9993
0
10
20
30
40
50
60
70
80
90
100
0 50 100 150 200 250
1
/m
R
S
A
 a
p
p
 (
1
/u
m
o
l)
1/[L-trp] (1/mM)
92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
high affinity of these compounds for the protein, only (S)-BIC14 and (R)-BIC35 allowed 
the analysis in pseudo-physiological conditions (aqueous solution). Rac- and (R)-
bicalutamide, (R)-BIC52 and rac-BIC60 allowed the analysis with PB (67 mM, pH 7.4)/1-
propanol 98:2; (R)-BIC33 with PB (67 mM, pH 7.4)/1-propanol 97:3; (S)-BIC20 and (S)-
BIC32 with PB (67 mM, pH 7.4)/1-propanol 96:4; (R)-BIC30, (R)-BIC59 , (R)-BIC51 PB 
(67 mM, pH 7.4)/1-propanol 94:6, as mobile phase. 
It is already known that the presence of an organic modifier may cause changes in 
the secondary or tertiary structure of the protein; moreover also the microenvironment 
around the HSA binding area may be modified [10]. These variations could affect the 
drug-protein binding process, thus we analyzed the variation of log k’ values of the 
bicalutamide analogues when changing the propanol concentration in the mobile 
phase (Fig. 5.5).  
From the observed trend (Fig. 5.5) it is clear that the presence of propanol highly 
affect the log k’ values, but it is also evident that the ranking of the compounds under 
A B
C
Fig. 5.4 (A) Chromatographic enantioresolution of rac-ketoprofen 60 µM; (B) chromatographic 
enantioresolution of rac-warfarin 60 µM; (C) chromatographic enantioresolution of N-benzoil-DL-
leucine 60 µM. Mobile phase was phosphate buffer (pH 7.4; 67 mM)/1-propanol (90:10, v/v); flow rate 
1 mL/min. 
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investigation it is not subject to significant variations. In order to compare all the 
bicalutamide analogues bound fractions, we decided to calculate this data starting from 
the value obtained using PB (67 mM, pH 7.4)/1-propanol 94:6 as mobile phase. 
Furthermore, the dependability of the column for ranking the new synthesized 
compounds for their HSA binding was checked by injecting in pseudo-physiological 
conditions additional drugs, whose bound fraction to the serum protein was already 
known (Table 5.1). A quite good agreement was found in the comparison of the bound 
fraction values experimentally obtained for the HSA binding and the literature data of 
these marker compounds [11]. 
The majority of the analogues showed a higher affinity to HSA comparing to the 
lead compound (Table 5.1). In particular, (R)-BIC51 and (R)-BIC59 showed the highest 
affinity (98.6% and 98.3%, respectively) and also the higher calculated Log P values 
among all the compounds under investigation (4.765 and 4.552, respectively). Since 
these molecules were modified with the introduction of a big substituent at the chiral 
stereocenter, then the increase of the lipophilicity of the α-carbon also increases the 
affinity of this class of compounds for the HSA. Furthermore, among all the newly  
synthesized analogues, (S)-BIC14 shows the lowest affinity for the protein, as well as 
the lowest predicted log P. In fact, this compound comes from the introduction of a polar 
amino group on the α-carbon of the lead compound. On the other hand, the ranking of 
0
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Fig. 5.5 Relationship between log k’ values of bicalutamide analogues obtained with the HSA-based 
column at various concentration of 1-propanol in the mobile phase. 
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the compounds based on the log P parameter does not mirror that one based on the 
bound fraction values. Therefore, even though the hydrophobicity is an important 
parameter in determining the interaction between this class of compounds and HSA, it 
does not appear to be the unique factor influencing this type of interactions. 
The significant difference in the binding percentage between the two enantiomers 
of the rac-bicalutamide, (R)-BIC and (S)-BIC (93.3% and 71.8%, respectively), proves 
the highly enantioselectivity in the binding ability of this protein [12]. It is well known that 
the clinical efficacy, as well as the toxicity, of a drug strictly depends from its free 
fraction.  It is therefore interesting to look at the free percentage of a drug derived from 
the following equation: 
 
F% = 100 – B%          eq. 5.4 
 
Table 5.1 Bound fraction (B%) obtained by affinity 
chromatography and predicted log P values. 
a
Calculated as the average of the results obtained by 
two injections. 
b
Calculated using online www.molinspiration.com/cgi-
bin/properties site (Molinspiration Property Engine 
v2009.01) 
c
Mobile phase: PB (67 mM, pH 7.4) 
d
Mobile phase: PB (67 mM, pH 7.4)/1-propanol 94:6 
Sample B%a miLog Pb
L-Trp 63.1c
Clonazepam 83.1c
rac-BIC(S) 71.8d 2.154
(S)-BIC14 72.5d 2.197
(R)-BIC35 90d 3.337
(R)-BIC52 90.3d 3.429
(R)-BIC 93.3d 2.154
(R)-BIC33 93.9d 3.416
(R)-BIC60 94.1d 3.579
rac-BIC60 94.2d 3.579
(S)-BIC32 97d 4.512
(S)-BIC20 97.4d 3.928
(R)-BIC30 98d 4.477
(R)-BIC59 98.3d 4.552
(R)-BIC51 98.6d 4.765
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In fact, small changes in the highest bound drug percentages correspond to large 
variations in their parallel free drug fractions, as we can appreciate in the table below 
(Table 5.2). Moreover, if we look at the ratio between the F% of the lead compound 
((R)-bicalutamide) and the F% of each of the compounds under investigation, it is clear 
how the former will have a higher pharmacological activity than its analogues, unless 
there are other events which will balance the binding properties. (R)-bicalutamide is 
about five times more bioavailable than the compound with the highest bound fraction, 
(R)-bic51 (Table 5.2). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.3 HSA binding site investigation by circular dichroism 
Competition experiments were carried out by circular dichroism, in order to identify 
the high affinity binding site of this class of compounds on HSA and RSA. In this way it 
was possible to determine the main differences between the binding properties of the 
two proteins. The change of the induced CD spectrum observed for a [protein]/[marker] 
complex 1:1 (15 µM) in the presence of increasing concentrations of rac-bicalutamide 
was monitored. It was not possible to study the behaviour of the newly synthesized 
Table 5.2 Comparison between the free fraction (F%) 
obtained with HSA by affinity chromatography. 
Sample F% F%bic/F%
rac-BIC(S) 28 0.24
(S)-BIC14 27.5 0.24
(R)-BIC35 9.8 0.68
(R)-BIC52 9.7 0.69
(R)-BIC 6.7 1
(R)-BIC33 6.0 1.1
(R)-BIC60 5.8 1.1
rac-BIC60 5.8 1.1
(S)-BIC32 2.9 2.3
(S)-BIC20 2.5 2.6
(R)-BIC30 1.9 3.4
(R)-BIC59 1.7 3.9
(R)-BIC51 1.3 4.9
96 
 
compounds with this technique because of their low solubility: the extremely low 
concentrations and the high amounts of organic modifier required have prevented form 
obtaining appreciable signals. The markers employed were chosen for their known 
ability to bind to specific binding area of these proteins: diazepam (selective binding to 
benzodiazepine site), ketoprofen (selective binding to site II) and bromophenol blue 
(selective binding to site III). Both diazepam and ketoprofen bind at site II on HSA, while 
the two markers bind at different binding sites on RSA. In this analysis rac-bicalutamide 
was used as the competitor, because of its spectroscopic characteristic. In fact, in order 
to make easier the experiments the marker should present absorption and an induced 
CD signal at lower energy with respect to the absorption of the competitor and the 
protein [12]. 
Any relevant change of the induced CD spectrum of ketoprofen and diazepam was 
observed upon adding increasing concentration of rac-bicalutamide up to 
[protein]/[marker]/[rac-bicalutamide] 1/1/6; suggesting an independent binding with site 
II and the benzodiazepine site on both the proteins investigated (Fig.5.6, 5.7). 
 When bromophenol blue was used as marker rac-bicalutamide resulted very 
efficient in increasing the induced CD spectra of [HSA]/[bromophenol blue] complex, 
suggesting a positive cooperative binding at bilirubin site, unlike the results obtained 
with RSA, were an independent binding was recorded (Fig. 5.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.6 Effect on the induced CD of ketoprofen bound to HSA (A) and RSA (B) upon addition of 
increasing concentration of rac-bicalutamide to the [HSA]/[marker] (A) and [RSA]/[marker] (B) 
complexes. 
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Fig. 5.7 Effect on the induced CD of diazepam bound to HSA (A) and RSA (B) upon addition of 
increasing concentration of rac-bicalutamide to the [HSA]/[marker] (A) and [RSA]/[marker] (B) 
complexes. 
Fig.5.8 Effect of the induced CD of bromophenol blue bound to HSA (a) and RSA (b) upon addition of 
increasing concentration of (R)-bicalutamide to the [HSA]/[marker] (a) and [RSA]/[marker] (b) 
complexes. 
98 
 
5.4 Conclusions 
 
A high amount of HSA was correctly immobilized onto the silica matrix, being the 
used method suitable to maintain the binding and enantiodiscriminating properties of the 
protein. The good enantioselectivity shown by the HSA-column makes it suitable for 
both bio-chromatographic and separative applications.  
All the compounds analyzed showed high affinity for the HSA (90%≥ B% ≤ 98.6), 
with the exception of (S)-BIC14 and the (S) enantiomer of the racemic lead compound 
(rac-bicalutamide). The majority of the analogues investigated showed a higher affinity 
to HSA comparing to the lead compound. The hydrophobicity highly influence the 
protein binding level of these compounds, but it seems not to be the only factor 
characterizing the biomolecular interaction. From the analysis of the calculated free 
fraction it is clear that the (R)-bicalutamide (lead) is about five times more bioavailable 
in the human body than the synthesized compound with the highest bound fraction, (R)-
BIC51. All these evidences should be taken into account during the design of optimized 
structures, in order to obtain the right balance between distribution and half-life of the 
new drugs. 
According to the results obtained with CD competition experiments carried out with 
HSA and RSA, an independent binding at benzodiazepines site and site II was recorded 
with both the proteins. In the case of HSA, a positive cooperative binding at bilirubin site 
can be hypothesized, unlike RSA, which has shown an independent binding at the 
same binding site. 
These data demonstrate the importance of getting distribution data with albumin 
from different species in early stages of drug discovery, in order to avoid 
misinterpretation of the experimental data obtained from the in vivo experiments 
conducted on animals. 
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Chapter 6 
Optical Biosensor analysis of Bicalutamide 
analogues interaction with human serum albumin 
and rat serum albumin 
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Abstract 
 
The binding of some novel bicalutamide analogues (see section 4.1) for the main 
plasma protein, albumin, was characterized by using optical biosensor technique (SPR). 
The study was carried out with, Human Serum Albumin (HSA) and Rat Serum Albumin 
(RSA), with the aim of highlighting the possible differences among species when 
performing pharmacokinetic studies. 
HSA and RSA were covalently immobilized on carboxymethyl dextran matrixes, 
via amine coupling allowing the binding properties of the protein to be maintained. The 
ranking of the bicalutamide analogues for their HSA and RSA bound fractions was 
performed, to compare the behaviour of the two albumins. The dissociation constants 
(KD) of the interaction between the lead compound, (R)-bicalutamide, and the two 
proteins were calculated. The RSA chip allowed also the KD evaluation for the RSA 
highly bounded compounds. Meaningful differences in the results obtained with the two 
serum proteins have been underlined.  
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6.1 Experimental 
 
6.1.1 Materials and methods 
Human serum albumin (HSA, essentially fatty acid free) was purchased from 
Calbiochem (La Jolla, CA, USA); rat serum albumin (RSA, essentially fatty acid free and 
globulin free) and (S)-warfarin were purchased from Sigma-Aldrich (Milan, Italy). 
Sodium dihydrogen phosphate dihydrate (NaH2PO4 x 2H2O) was purchased from Merck 
(Darmstadt, Germany). Sodium chloride, potassium chloride were from Sigma-Aldrich 
(Buchs, Switzerland); rac-warfarin was obtained from Sigma-Aldrich (Steinheim, 
Germany). Sodium acetate and sodium hydroxide were from Fluka (Buchs, 
Switzerland). Dimethyl sulfoxide (DMSO) was purchased from Fisher Scientific 
(Switzerland). 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC), N-
hydroxysuccinimide (NHS), ethanolamine-HCl and the sensor chip with 
carboxymethylated matrix CM5 were from Biacore (GE Healthcare). Synthesis and 
physicochemical characterization of the bicalutamide analogues under investigation 
have been described previously (see section 4.2.1) [1-4]. The structures of the 
compounds are reported in Fig. 6.1. 
The running buffer was prepared by adjusting the pH of NaH2PO4 x 2H2O solution 
with the addition of 1 mM NaOH.  Twice distilled and degassed water deionized and 
filtered with Millipore Elix 3 was used for mobile phase’s preparation. The buffer 
solutions were filtered through a 0.22-µm membrane filter and degassed before use. 
 
6.1.2 Instrumentation 
Surface plasmon resonance analyses were performed by using Biacore X100 
optical biosensor with Biacore X100 Plus Package (Biacore AB, Uppsala, Sweden). The 
system was thermostated at 25°C and equipped with research-grade CM5 sensor chips 
(Biacore). Biosensor data were analyzed using Biacore™ X100 2.0 Evaluation 
Software. Data processing was performed with BIAevaluation software. 
 
6.1.3 Serum albumin immobilization 
The human serum albumin surface was prepared by using standard amine-
coupling method [5]. The HSA was coupled through his surface amine groups via amine  
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bonds with the CM5 sensor chip of the Biacore X100 instrument. The running buffer 
was PBS (Phosphate buffered saline: 10 mM phosphate buffer, 137 mM sodium  
chloride, 2.7 mM potassium chloride, pH 7.4) and the temperature was set at 25 °C. The 
protein was dissolved at 50 μg/mL in 10 mM Sodium Acetate pH 5.0. Carboxyl groups 
on the dextran layer of the chip were activated by injecting a 1:1 mixture of 0.4 M N-
ethyl-N-(3-dimethylaminopropyl) carbodiimide (EDC) and 0.1 M N-hydroxysuccinimide 
(NHS) for 7 min at a flow rate of 10 μL/min. The HSA solution was injected in channel 2 
Fig. 6.1 Structures of (R)-bicalutamide and its analogues. 
(S)-BIC14 (S)-BIC20
(S)-BIC32 (R)-BIC33
(R)-BIC51
(R)-BIC35
(R)-BIC52 (R)-BIC59
rac-BIC60 (R)-BIC63
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and was allowed to react for 7 min at a flow rate of 10 μL/min. The remaining carboxyl 
groups were blocked by injecting a solution 1 M ethanolamine for 7 min at a flow rate of 
10 μL/min. The protein was immobilized only in one channel of the sensor chip in order 
to monitor the possible non-specific bindings by means of the second channel. The 
reference control channel was only activated with 1:1 EDC/NHS mixture, and then 
treated with ethanolamine to block NHS-ester groups. The HSA immobilization 
experiment is summarized in the sensorgram shown in Fig. 6.2, where the optical 
biosensor response (resonance units) is reported as a function of time.  
The protein was immobilized on a second CM5 chip, in order to determine the 
reproducibility of the assays at different immobilization levels of the protein. The second 
immobilization experiment was carried out in manual run conditions, in order to control 
the run interactively. The protein was dissolved at 25 μg/mL in 10 mM Sodium Acetate 
pH 5.0. The chip was activated by injecting a 1:1 mixture of EDC/NHS for 7 min at a 
flow rate of 5 μL/min. The HSA solution was injected in channel 2 and was allowed to 
react for 12 min at a flow rate of 5 μL/min (6 injections of 2 min each). The remaining 
carboxyl groups were blocked by injecting a solution 1 M ethanolamine for 7 min at a 
flow rate of 5 μL/min. Two pulse of 12 s of 50 mM NaOH were injected to wash non 
covalently bound protein and stabilize the baseline. 
Rat serum albumin was also immobilized on the dextran matrix surfaces of two 
different sensor chips, following the same procedure as the first HSA chip. The 
concentration of RSA solutions utilized for the immobilizations were 50 µg/mL and 20 
µg/mL for the first chip and the second one, respectively. 
After the immobilization the sensor chip surfaces were stabilized by various 
injections of running buffer at 30 μL/min all over the night. 
All the sensor chips were stored in a refrigerator every night after the experiments, 
in a 50 ml tube containing running buffer so that the support was completely covered. 
 
6.1.4 Preparation of sample solutions 
Rac-warfarin and S-warfarin were freshly prepared as 1 mg/mL stock solutions 
and diluted with running buffer (PBS) immediately prior to use. A suitable range of 
concentrations (1 µM - 300 µM) was obtained by diluting the stock solutions with the 
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running buffer. In order to avoid disturbance of the baseline, all the dilutions were done 
directly into the analysis tubes. 
All the compounds under investigations were analyzed in the presence of DMSO 
(5% v/v) in the running buffer as well as in the sample solutions. The running buffer for 
these analyses was prepared as already described: firstly, a 1.05 x PBS was prepared 
and the pH was adjusted to 6.85 by addiction of NaOH so that after adding the 5% v/v 
of DMSO the pH value became 7.4 [6]. R-bicalutamide, rac-warfarin and S-warfatin 
stock solutions were prepared in DMSO at 2 mg/mL, whereas all the bicalutamide 
analogues were stocked in DMSO at 1 mg/mL. Immediately prior to analysis, stock 
samples were diluted 1:20 with 1.05 x PBS; further dilutions were made by diluting the 
previous solutions with the running buffer containing 5% of DMSO. The running buffer 
and the samples solutions should contain the same percentage of DMSO, because of 
the high refractive index contribution of DMSO which may cause important variations in 
the final SPR signals. 
 
6.1.5 Solvent Refractive Index correction 
A DMSO calibration procedure was included in the assay protocols, in order to 
eliminate the bulk responses caused by the presence of a high refractive index solvent 
(DMSO). Especially when working with small molecules, the solvent refractive index 
correction becomes essential. In fact, in this case the expected analytes binding 
responses and those due to the bulk response could have the same order of magnitude 
and lead to big misunderstanding of the final data. So that a series of eight buffer 
solutions containing concentrations of DMSO ranging from 4.5 - 5.8 % (v/v) were 
injected in sequence over reference and HSA surfaces. A DMSO calibration plot was 
built by plotting the difference in response between HSA and reference flow cells versus 
the response in the reference flow cell [7]. The DMSO calibration plot was built every 
day, prior to start with the binding analysis. All data collected were fixed with this curve. 
 
6.1.6 Ranking analysis 
The running buffer used was PBS 10 mM with 5% (v/v) DMSO, pH 7.4. In the 
ranking format the compounds were injected over the HAS and RSA surfaces at a 
concentration value of 25 µM, with the flow rate set at 10 µL/min. Ligands were allowed 
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to associate with the protein for 60 s and dissociation was recorded for 10 min. After 
each injection a buffer injection was included to check the possible carry-over of the 
analyte to the next cycle and to re-stabilize the chip surface. All samples were injected 
in duplicate. 
 
6.1.7 Equilibrium dissociation constant determination  
Rac-warfarin, S-warfarin and the lead compound of this class of molecules, (R)-
bicalutamide, were investigated for their HSA and RSA equilibrium dissociation 
constants (KD) determination. (R)-BIC51, (S)-BIC20 and (S)-BIC32 were also analyzed 
for the determination of their RSA dissociation constants. A wide range of analyte 
concentrations were tested over the albumin chips at a flow rate of 30 µL/min, at 25 °C. 
Buffer blanks were injected periodically in order to clean the chip surface preventing the 
accumulation of the analyte on the sensor chip. All sensorgrams were processed by 
using double referencing method (see section 4.2.6). Rac-warfarin and S-warfarin were 
analyzed in the presence and in the absence of DMSO in the running buffer, instead 
(R)-bicalutamide and its analogues were always analyzed in the presence of 5% (v/v) of 
DMSO in the running buffer. The association phase was followed for 60 s, being the 
kinetic of the interaction very fast. The dissociation phase was followed for 60 s when 
rac-warfarin, (S)-warfarin and (R)-bicalutamide were the analytes; 10 min were needed 
when the bicalutamide analogues were used as analytes. Equilibrium responses at 
different concentrations were plotted as a function of drug concentrations and then fitted 
with the specific interaction model. Concerning (R)-bicalutamide and its analogues, a 
single-site interaction model was applied. This approach leads to a unique KD which 
corresponds to the higher affinity site constant: 
 
     
     [ ]
   [ ]
          eq. 6.1 
 
where     is the SPR response at equilibrium;      the maximum capacity of the ligand 
for the ligate; [L] the analyte concentration and   the dissociation constant. 
Rac-warfarin dissociation constant determination was carried out by fitting the 
equilibrium responses obtained with an independent two site interaction model, in order 
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to identify the KD values of its primary and secondary affinity binding sites on the 
protein: 
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          eq. 6.2 
 
A four-site model was used to calculate the affinity of (S)-warfarin with RSA, in 
order to find not only the KD value corresponding to its primary binding site on the 
protein, but also the KD of the lower affinity binding sites where weak interactions 
contribute to the realization of the drug-protein complex. This was possible by using the 
following equation: 
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     eq. 6.3 
 
6.2 Results and Discussion 
 
6.2.1 Immobilization of serum albumin 
HSA and RSA were immobilized on a CM5 chip. This carboxymethylated dextran 
matrix represents the most versatile chip available; it holds an excellent chemical 
stability and provides a high capacity to immobilize a wide range of ligands, such as 
proteins, carbohydrates, lipids, nucleic acids and small organic molecules. The amine 
coupling method was used to immobilize the two proteins. A typical sensorgram of the 
serum albumin immobilization procedure is shown in Fig. 6.2. Since the covalent 
binding occurs trough primary amine groups on the proteins, the running buffer and the 
buffer used to dissolve the protein should not contain primary amine groups. Moreover, 
in order to maximize the efficiency of the immobilization step a suitable electrostatic pre-
concentration of the proteins on the sensor chip must be achieved. To this purpose the 
pH of the immobilization buffer was 5, a value between the pka of the surface (pH > 3.5) 
and the isoelectric point (pI) of the ligand (pI = 5.67 [8]); so that the ligand acquires a 
positive charge and results in an efficient pre-concentration into the negatively charged 
carboxymethyl dextran matrix. 
The reference channel was reacted as the active channel, without anchoring the 
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protein. In this way all the non-specific binding phenomena on the biosensor surface 
were monitored. After the first HSA immobilization, the amount of immobilized protein 
results in 16114 RU.  
In order to determine the reproducibility of the assays, another HSA immobilization 
was performed following the same chemical strategy, but using a lower HSA 
concentration and the manual run windows of the BiacoreTM X100 2.0 Control software, 
in order to check in real time the amount of protein immobilized. The final amount on the 
second sensor chip corresponds to 5572 RU (Fig. 6.3). The lower immobilization levels 
reached ensure to avoid artefacts due to high ligand density on the chip and mass-
transport limited binding analysis. Moreover, it was possible to assess whether different 
protein densities could influence the data collected. 
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Fig. 6.2 Sensorgram of the Human Serum Albumin immobilization to the carboxymethyl dextran 
matrix: (1) buffer baseline stabilization; (2) EDC/NHS mixture add; (3) buffer re-equilibration; (4) HSA 
in acetate buffer add (7 minutes of reaction); (5) buffer washes; (6) block of non-coupled activated 
CMD sites with ethanolamine (7 min of reaction); (7) baseline stabilization. 
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The binding of rac-warfarin was used to check that the two immobilization 
processes did not involve the principal binding site on the protein. As a result the 
experimental KD of the reference compound obtained with both two chips were in 
agreement to that reported in the literature (see section 6.2.3) [9, 10]. 
Concerning RSA, the two coupling procedures result in 12000 RU and 8910 RU of 
protein immobilized, with the two different CM5 chips. Also in this case S-warfarin was 
used as reference to check the dependability of the RSA sensor chip (see section 6.2.3) 
[11 - 13]. 
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Fig. 6.3 Sensorgram of the Human Serum Albumin immobilization to the carboxymethyl dextran matrix 
performed in manual run mode: (1) buffer baseline stabilization; (2) EDC/NHS mixture add; (3) buffer 
re-equilibration; (4) HSA in acetate buffer add (7 minutes of reaction); (5) buffer washes; (6) block of 
non-coupled activated CMD sites with ethanolamine (7 min of reaction); (7) baseline stabilization. 
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6.2.2 Ranking analysis 
HSA investigation 
(R)-bicalutamide and seven of its analogues, (S)-BIC14, (S)-BIC20, (S)-BIC32, 
(R)-BIC33, (R)-BIC51, (R)-BIC59 and rac-BIC60, were ranked for their HSA binding 
level. To this purpose only one concentration value of ach compound were utilized. The 
analytes were floated over the HSA surface at 25 µM, at low flow rate (10 µL/min) in 
order to promote the small molecule-protein interactions. The concentration chosen was 
high enough to give a reasonable signal but also low enough to avoid misinterpretation 
of data due to interaction with several binding sites on the protein [7]. The SPR 
maximum response after a 60 s injection was recorded for each of the compounds 
analyzed. Being the SPR response directly correlated with the specific molecular mass 
of the analytes, all the data collected from this analysis were divided for this value, in 
order to obtain comparable molar values (Fig. 6.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(R)-BIC51, (R)-BIC59, (S)-BIC20 and (R)-BIC33 showed higher HSA affinity than 
the lead compound, (R)-bicalutamide; whereas (S)-BIC32, (S)-BIC14 and rac-BIC60 
possess lower affinity for the protein. All the strongly bound compounds show a 
Fig. 6.4 Ranking analyses of bicalutamide analogues performed with the HSA chip at a concentration 
of 25 μM in PBS 10 Mm + 5% DMSO, pH 7.4. Binding data were adjusted for the molecular weights of 
each compounds. 
80
70
60
50
40
30
20
10
0
(1
0
0
 x
 R
U
)/
D
a
113 
 
voluminous and lipophilic substituent in their structure; on the contrary the lowest 
binders have hydrophobic (as in the case of (S)-BIC14) or slightly voluminous 
substituents ((S)-BIC32 and (rac)-BIC60). Therefore we can hypothesize that the 
presence of a large, lipophilic substituent on the chiral stereocenter of the reference 
compound allows a better stabilization of the newly synthesized molecule in the binding 
pocket of the protein, thus increasing the affinity for the protein, as well as the stability of 
the specific complex. 
It was possible to compare the HSA affinity data of this class of compounds 
achieved with both SPR and HPALC techniques (see Chap. 5). What immediately 
stands out is that in both cases (R)-BIC51, (R)-BIC59, (S)-BIC20 and (R)-BIC33 
showed the highest affinity for the protein; as well as in both cases (S)-BIC14 is one of 
the compounds with the lowest affinity for the HSA. On the other hand, (S)-BIC32 and 
rac-BIC60 showed different behavior with the two techniques. 
The achieved results have proven the suitability of the SPR technique as a high-
throughput screening method in the target binding level identification of new classes of 
pharmaceutical compounds. The comparison of this technique with the more 
conventional affinity chromatography highlights at once the major advantages of SPR 
biosensor technique. First of all, only few micrograms of protein are required to perform 
a chip immobilization and little volumes of buffers and samples are needed during all 
the experiments. Furthermore, there is a huge improvement in the analysis time: usually 
20-25 min are needed for ligand immobilization (against the 2 days needed to 
immobilize a ligand on the silica matrix support in HPALC) and only 4-5 min are 
required for a complete characterization of a ligand-analyte interaction (60 min for the 
most bounded compounds in HPALC). Therefore this technique resulted well-suited to 
classify rapidly newly synthesized compounds in low-, medium- and high-level binders. 
 
RSA investigation 
All the compounds showed in Fig. 6.1 were tested for their RSA affinity on the 
basis of the binding level achieved after injection of a single concentration (25 µM), in 
the same experimental condition used for the previous HSA experiments. The RSA 
ranking results are shown in the figure below (Fig. 6.5).  It was possible to compare 
these data with the SPR and HPALC data acquired with human serum albumin. 
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(R)-BIC51 and (S)-BIC20 showed the highest affinity for RSA, whereas (S)-BIC14 
represents the more weakly bound analogue. Therefore also in the case of RSA the 
presence of a big, lipophilic substituent on the chiral stereocenter of the reference 
molecule allows a better accommodation of the analogues in the binding pocket of the 
protein, as already seen with HSA. 
One of the major differences involves the binding ability of (R)-BIC59, which is one 
of the strongly bound compounds to HSA, but it shows very low affinity for RSA. The 
same result was found for (R)-BIC33, characterized by a low binding ability for RSA, 
unlike the results obtained with HSA, by using both SPR and HPALC techniques. These 
molecules have substituents characterized by a relatively good flexibility, compared with 
the RSA highly bounded analogues. This characteristic probably helps the stabilization 
of the HSA-drug complex, but not the RSA-drug interaction. Another interesting 
difference is the influence of the benzonitrile substituent, which gave opposite effects on 
the binding to the two proteins. This is clear if we look at the binding level reached with 
(R)-BIC35 and (R)-BIC52, when both RSA and HSA were used. In the first case, the 
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Fig. 6.5 Ranking analyses of bicalutamide analogues performed with the RSA chip at a concentration 
of 25 μM in PBS 10 Mm + 5% DMSO, pH 7.4. Binding data were adjusted for the molecular weights of 
each compounds. 
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presence of this substituent increases the affinity for the target protein, whereas no 
significant changes were found in the case of HSA. In both cases, the adding of a 
fluorine atom to the structure of (R)-BIC52 determines the increase of the affinity. This 
last effect is more evident with RSA, than with HSA. 
RSA demonstrates a huge enantioselectivity effect in its binding ability and also in 
this case big differences with the HSA were found. The racemate form of the lead 
compounds results in a higher affinity for the RSA than its (R) enantiomer; the 
investigation of rac-BIC60 and (R)-BIC60 led to the same results. We can therefore 
hypothesize a higher interaction of the (S) enantiomers of both the compounds 
investigated with rat albumin. The HSA investigation of the same analogues by means 
of HPALC resulted in very different conclusions: concerning the lead compound, the (R) 
enantiomer showed a bound percentage much higher than those obtained with the (S) 
enantiomer; instead (R)-BIC60 and rac-BIC60 possess quite the same binding affinity 
for the protein. 
These data confirm that the extrapolation of values obtained with albumin from 
different species should be done carefully, since these very similar proteins often show 
big differences in their binding ability. 
 
6.2.3 Equilibrium dissociation constants determination 
The compounds under investigation bound reversibly to both HSA and RSA, so 
that the association and dissociation phases of the interaction were followed. 
First of all, rac-warfarin was investigated for its binding to the human serum 
protein, in order to check that the immobilization step does not impact the obtained 
binding results when compared to the results obtained in solution. The interaction was 
monitored firstly in pseudo-physiological condition (PBS 10 mM, pH 7.4) and after in the 
presence of 5% (v/v) of DMSO in the running buffer. During the injection of all the set of 
concentrations under investigation (about 1 µM - 300 µM) a steady state was reached in 
few seconds; also the dissociation occurred very rapidly when the analyte solution was 
replaced with the running buffer. The Figure 6.6 showed the overlaid SPR responses 
plotted as a function of time. It is well known that rac-warfarin binds to two different 
classes of binding sites on the HSA, so using a two sites binding equation on Biacore’s 
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software (eq. 6.2) it was possible to fit equilibrium responses at different concentrations 
to obtain the two equilibrium dissociation constants (Fig. 6.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The experimental KD values (Table 6.1) are in good agreement to those reported in 
literature obtained by using the same technique [9], as well as with those obtained by  
independent techniques [10]. These data prove that the protein was correctly 
immobilized on the sensor chip and that the presence of DMSO does not disturb the 
binding ability of the anchored protein. 
In order to establish the reliability of the RSA sensor chip, (S)-warfarin was used 
as reference compound. The same experimental condition and samples preparation as 
for the HSA chip validation were adopted for the RSA chips. The concentrations used 
ranged from 1 µM to 300 µM for the analysis in pseudo-physiological conditions (PBS 
10 mM, pH 7.4), and from 4 µM to 600 µM for the analysis in the presence of 5% of  
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Fig.6.6 Corrected overlays sensorgrams for rac-warfarin binding to human serum albumin, obtained 
using different rac-warfarin concentrations (about 1 µM - 300 µM). (A) Buffer: PBS 10 mM, pH 7.4 (B) 
Buffer: PBS 10 mM + 5% (v/v) DMSO, pH 7.4. 
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Fig. 6.7 Response data of HSA binding at equilibrium versus rac-warfarin concentration. (A) Buffer: 
PBS 10 mM, pH 7.4 (B) Buffer: PBS 10 mM + 5% (v/v) DMSO, pH 7.4. 
 
HSA
(16113.9 RU)
HSA
(557.4 RU)
Literature
KD1 1.6 x 10
-6 M a
2.4 x 10-6 M b
7.2 x 10-6 M a
1.8 x 10-6 M b
6.8 x 10-6 c
4 x 10-6 d
KD2 3.88 x 10
-4 M a
1.8 x 10-4 M b
9.9 x 10-4 M a
3.3 x 10-4 M b
1.0 x 10-4 c
1.49 x 10-4 d
Table 6.1 Rac-warfarin KD values. 
a
 Buffer: PBS 10 mM, pH 7.4 
b
 Buffer: PBS 10 mM + 5% (v/v)     
DMSO, pH 7.4 
c
 [9] 
d
 [10] 
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DMSO. According to literature data, (S)-warfarin binds at four different binding pockets 
in the rat albumin structure; in particular RSA has two sets of binding sites: one high- 
affinity site and three of much lower affinity [11]. Therefore, a four-site model was used 
to calculate the affinity of (S)-warfarin to this protein (eq. 6.3), which yielded four 
different KD values: 7.625 x 10
-6 M, 9.481 x 10-5, 5.752 x 10-4 and 2.005 x 10-4 (Fig. 6.8). 
These data are in good agreement with the values found in literature [11-13]. The same 
experiments was repeated different times on the same RSA sensor chip and confirmed 
with the second one. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.6.8 (A) Corrected overlays sensorgrams for (S)-warfarin binding to rat serum albumin, obtained 
using different (S)-warfarin concentrations (about 1 µM - 300 µM) in pseudo-physiological condition 
(PBS 10 mM, pH 7.4). (B) Response data at equilibrium versus (S)-warfarin concentration.  
R
e
s
p
o
n
s
e
(R
U
)
Time (s)
R
e
s
p
o
n
s
e
(R
U
)
Concentration (M)
A
B
119 
 
Since (R)-bicalutamide showed very low solubility, its KD determination was 
conducted in the presence of 5% (v/v) of DMSO in the running buffer, as well as in the 
sample solutions, with both HSA and RSA sensor chips. A wide range of (R)-
bicalutamide concentrations were floated over the sensor chip surfaces, a series of 
concentrations ranging from 3 µM to 200 µM when HSA was the ligand; and from 5 µM 
to 350 µM when RSA was used as the ligand. Also in this case both the association and 
dissociation phases were very rapid, as we can see in the Figure 6.9 A and 6.10 A. A 
single-site model (eq. 6.1) was used to fit the binding data obtained (Fig. 6.9 B, 6.10 B). 
The value of KD calculated with the highest density HSA sensor chip was 1.8 x 10
-5 M, 
value in good agreement with those obtained in the same experimental conditions with 
the lowest density chip (1.6 x 10-5 M). The dissociation constant found with the RSA 
chip was 3.8 x 10-4 M, one order of magnitude lower than those observed with HSA. 
The data confirm once again the importance of studying the drug distribution with 
albumins from different species in an early phase of drug discovery. 
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Fig.6.9 (A) Corrected overlays sensorgrams for (R)-bicalutamide binding to human serum albumin, 
obtained using different (R)-bicalutamide concentrations (about 3 µM - 200 µM). (B) Response data at 
equilibrium versus (R)-bicalutamide concentration. Buffer: PBS 10 mM + 5% (v/v) DMSO, pH 7.4. 
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RSA-bicalutamide analogues study 
The RSA sensor chip was used to evaluate the dissociation constants of the 
complexes formed between the highly bound compounds and the RSA. A wide range of 
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Fig.6.10 (A) Corrected overlays sensorgrams for (R)-bicalutamide binding to rat serum albumin, 
obtained using different (R)-bicalutamide concentrations (about 5 µM - 350 µM). (B) Response data at 
equilibrium versus (R)-bicalutamide concentration. Buffer: PBS 10 mM + 5% (v/v) DMSO, pH 7.4. 
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concentrations (2 µM – 90 µM) of (R)-BIC51, (S)-BIC20 and (S)-BIC32 were injected 
over the RSA surface. Because of the poor solubility of the tested compounds all the 
analysis were conducted in the presence of 5% (v/v) of DMSO. After 60 s injection a 
steady-state plateau was reached. The dissociation phases were followed for 10 min, 
since a complete regeneration of the sensor chip was difficult to achieve. The binding 
responses of each compound plotted as a function of time are reported in Fig. 6.11. A 
single site equation was applied to analyze the plot of the SPR equilibrium responses at 
different analyte concentrations (Fig. 6.12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After an accurate evaluation of the data collected, KD values of 3.18 x 10
-5 M, 5.55 
x 10-5 M and 6.41 x 10-5 M were calculated for (R)-BIC51, (S)-BIC20 and (S)-BIC32, 
respectively. The experimental KD obtained are consistent with the ranking results 
discussed above (see section 6.2.2). 
Fig.6.11 Corrected overlays sensorgrams for (A) (R)-BIC51, (B) (S)-BIC20 and (C) (S)-BIC32 binding 
to rat serum albumin, obtained using different analyte concentrations (about 2 µM - 90 µM). Buffer: 
PBS 10 mM + 5% (v/v) DMSO, pH 7.4. 
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6.3 Conclusions 
 
Human serum albumin and rat serum albumin were immobilized on CM5 sensor 
chips via amine coupling to investigate the binding parameters of some novel 
bicalutamide analogues with these two proteins. Two different immobilization processes 
were carried out for each protein, leading to different protein immobilization levels. Rac-
warfarin and (S)-warfarin were used to evaluate the reliability of the immobilization 
steps, for both HSA and RSA. Good correlation of the binding data obtained with these 
sensor chips and those already published was found. 
The bicalutamide analogues under investigation were ranked for their HSA and 
RSA binding level and significant differences were observed with the two different 
proteins. The RSA ranking results were also compared with the HSA data obtained with 
the HPALC study (see Chapter 5). 
Fig. 6.12 Response data at equilibrium versus (A) (R)-BIC51, (B) (S)-BIC20 and (C) (S)-BIC32 
concentrations. Buffer: PBS 10 mM + 5% (v/v) DMSO, pH 7.4. 
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The KD evaluation of the lead of this class of compounds, (R)-bicalutamide, was 
conducted with both HSA and RSA, using a single site equation to fit the SPR 
responses observed. Also in this case a huge difference was found, being the affinity for 
HSA one order of magnitude higher than those for RSA.  
Some of the bicalutamide analogues were analyzed for their RSA KD binding 
constants, by using the RSA surface. The values extrapolated are consistent with the 
ranking data obtained before with the first RSA sensor chip. 
All the differences in the bicalutamide analogues behavior against the two proteins 
highlighted in this work should be carefully taken into account during the extrapolation of 
the in vivo distribution data obtained in preclinical studies to humans. 
This work makes evident the ability of the SPR technique for screening libraries of 
newly synthesized compounds for their affinity to the serum carrier albumins. A clear 
and rapid structure-activity study in early stages of drug discovery can be achieved with 
this technique allowing a rational design of the new pharmacological entities. 
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Conclusions 
 
The current work demonstrates the usefulness of a multi-methodological approach 
to provide a better elucidation of biorecognition processes. In particular our attention 
was focused on the albumin binding of novel synthesized class of pharmaceutical 
compounds and plasma proteins from different species, HSA and RSA. Moreover the 
interaction between new chemical entities and their biological target have been 
investigated. The use of orthogonal analytical techniques was proved to be the key 
strategy to obtain a deeply overview of the analysed processes. 
Three different classes of compounds, which possess different pharmaceutical 
functions have been studied: 5-Imino-1,2,4-thiadiazoles and quinazolines derivatives as 
glycogen synthase kinase 3b (GSK-3b) and phosphodiesterase 7 (PDE7) inhibitors; 
tocainide analogues as sodium channel blockers useful in the treatment of myotonic 
syndromes and bicalutamide analogues as anti-androgen drug used in the treatment of 
prostate cancer. The distribution behavior of each class of compounds was studied 
through three different analytical techniques: affinity chromatography (HPALC), circular 
dichroism (CD) and optical biosensor. Furthermore the optical biosensor technique was 
also applied to characterize the binding of the bicalutamide analogues with their 
biological target, the androgen receptor. 
 The affinity chromatography (HPALC) studies were conducted to rank the HSA 
binding level of each class of compounds, allowing the identification of the higher and 
lower bounded compounds to the protein. These data are very helpful to optimize the 
synthesis of novel pharmaceutical compounds, when a better distribution in the human 
body is required. In fact, albumin binding of drugs has an important role for the drug 
activity in vivo; furthermore, the binding of poor soluble compounds with plasma 
proteins improves also their solubility and their transport throughout the body. Since 
interactions with other drugs or endogenous factor for the same binding area can lead 
to significant alterations in the free drug concentration, the HSA based column was also 
utilized to evaluate the principal binding sites of the molecules under investigation on 
the protein structure. The displacement information obtained with this technique was 
then confirmed through CD, an in solution analytical technique which loses the 
drawback of the immobilization step, needed in the HPALC analysis.  
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Concerning the tocainide and bicalutamide analogues the same study was 
conducted using RSA as target. An interesting evaluation of differences among species 
has been highlighted. The extrapolated data suggests the relevance to assess the 
reliability of the operation of extrapolation of pharmacokinetic data obtained with 
animals to humans in early stages of drug discovery. 
The bicalutamide analogues were also screened for their HSA and RSA binding 
levels through the optical biosensor technique. All the compounds under investigation 
were rapidly tested over the HSA and RSA surfaces providing not only qualitative 
information on weather a molecule binds or not to the proteins but also quantitative 
evaluation of the bond strength. In fact, the highly bounded compounds have been also 
analysed in terms of KD values of the complex created with the RSA. The comparison of 
these data with those obtained through the chromatographic technique showed the 
reliability of this technique in characterizing strong drug-protein interactions in a high 
throughput screening mode: short time for the analysis and the miniaturization of the 
system represent two of the major advantages of this analytical technique. 
Finally a detailed description of the bicalutamide analogues-androgen receptor 
recognition process was obtained by means of an androgen receptor sensor chip. A 
rapid screening of these new compounds for their androgen receptor binding levels was 
obtained. This analysis allows the selection of newly analogues with higher affinity for 
the target than the reference compound.  Moreover, a careful kinetic analysis has been 
carried out with some of the compounds under investigation, providing a more detailed 
picture of the bio-recognition process mechanism. 
The development of a reliable multi-methodological method, as the one discussed 
in this thesis, represent the best way to approach the study of the recognition processes 
that govern the biological phenomena, providing important structure-activity relationship 
details in early phases of drug discovery.  
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Addendum 
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Summary in Italian 
 
Il lavoro di ricerca svolto dalla Dott.sa Cecilia Fortugno durante il triennio di 
Dottorato in Chimica è focalizzato sullo studio dei fenomeni di bio-riconoscimento 
esistenti nei processi biologici. Nelle prime fasi dello studio del farmaco questo tipo di 
studio è di fondamentale importanza, per poter caratterizzare  nuovi target biologici e 
sviluppare nuove molecole ‘lead’. Lo studio di questi fenomeni permette inoltre la 
caratterizzazione del profilo farmacocinetico dei nuovi farmaci in via di sviluppo in fasi 
precoci dello studio del farmaco (parametri ADMET: Assorbimento, Distribuzione, 
Metabolismo, Eliminazione e Tossicità), permettendo di selezionare sin da subito i 
composti più promettenti e di tralasciare invece quelli con caratteristiche negative, con 
un conseguente risparmio notevole di tempo e denaro. 
Tutto il lavoro è centrato sulla caratterizzazione del legame tra molecole di nuova 
sintesi, interessanti dal punto di vista farmacologico, e le loro proteine bersaglio. Lo 
studio è stato condotto utilizzando un approccio multi-metodologico, che ha previsto 
l’uso di tre tecniche analitiche: cromatografia di affinità ad alta pressione (HPALC), 
dicroismo circolare (CD) e Biosensore Ottico. L’utilizzo di queste tecniche in sinergia ha 
permesso di ottenere una chiara e completa visione dei processi di bio-riconoscimento 
in studio. 
In particolare, è stato analizzato il legame di molecole di nuova sintesi alla  
proteina più abbondante nel plasma, la sieroalbumina umana (HSA). Questa proteina 
possiede un ruolo fondamentale nel trasporto di farmaci, metaboliti e fattori endogeni; 
per questo lo studio del meccanismo di legame dei nuovi farmaci all’HSA è di 
fondamentale importanza per caratterizzare la distribuzione del farmaco. Attraverso le 
tecniche sopra citate è stato possibile ottenere un ranking delle diverse classi di 
composti in analisi per il loro legame alla proteina, permettendo di individuare 
facilmente i composti con caratteristiche farmacocinetiche più vantaggiose; inoltre, con 
l’utilizzo di specifici marker sono stati effettuati studi di spiazzamento con lo scopo di 
individuare i siti a più alta affinità di questi composti sulla proteina. 
Parte essenziale del lavoro è stata lo studio del legame di farmaci in via di 
sviluppo a sieroalbumine di diverse specie; in particolare HSA e RSA (sieroalbumina di 
ratto). Infatti, l’utilizzo di modelli animali negli esperimenti di distribuzione effettuati in 
vivo rappresenta un punto critico degli studi farmacocinetici. Con questo lavoro è stato 
possibile evidenziare come le piccole differenze presenti nella sequenza amminoacidica 
delle due proteine possano portare a significative differenze nella loro struttura 
tridimensionale che si rifletteranno quindi sulla loro capacità di legame e sulla loro 
stereoselettività. Ottenere queste informazioni in fasi precoci dello studio del farmaco  
permetterebbe un migliore confronto tra i dati ottenuti tramite esperimenti in vitro e i dati 
ottenuti con esperimenti sull’animale, facilitando così la successiva estrapolazione di 
questi dati all’uomo.  
In ultimo, per mezzo del biosensore ottico è stato analizzato il legame di una serie 
di potenziali antitumorali di nuova sintesi con il loro target biologico (recettore 
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androgeno). Questa tecnica permette la determinazione delle costanti di affinità (KD) dei 
complessi in analisi e delle  costanti cinetiche che guidano questi processi (kon e koff).  
All’interno dei tre anni di dottorato la Dott.sa Fortugno ha svolto un periodo di 
ricerca di circa un anno presso l’Università di Ginevra, School of Pharmaceutical 
Sciences (con la quale è stato stretto un accordo di co-tutela, tutors Profs. Pierre Alain 
Carrupt e Jean Luc Veuthey), usufruendo di una borsa Marco Polo per un periodo di sei 
mesi; ha partecipato a diversi convegni nazionali e internazionali presentando due 
comunicazioni orali e due comunicazioni poster; è inoltre coautrice di due pubblicazioni 
su quotate riviste internazionali (European Journal of Pharmaceutical Sciences, Journal 
of Chromatography B), e di altri due articoli accettati per la pubblicazione.   
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Summary in French 
 
Le travail de recherche developpé pendant le Doctorat en Chimie se focalise sur 
l'étude des phénomènes de bioreconnaissance existante dans les processus 
biologiques. Dans les premieres phases d’étude du médicament, ce type d'étude est 
très important pour pouvoir caractériser de nouveaux target biologiques et developer de 
nouvelles molécules “lead”. De plus, l'étude de ces phénomènes permet la 
caractérisation du profil pharmacocinétique de nouveaux médicaments dans les phases 
précoces d’étude du médicament (paramètres ADMET: absorption, Distribution, 
Métabolisme, Élimination et Toxicité), en permettant de sélectionner dès le début les 
composants les plus prometteurs et de passer, au contraire, sur ceux avec des 
caractéristiques négatives, en conséquence en gagnant du temps et d’argent. 
Tout le travail se fonde sur la caractérisation de la liaison entre les nouvelles 
entités chimiques, qui sont intéressant du point de vue pharmacologique et leurs 
protéines-target. L'étude a été réalisée en utilisant une approche multiméthodologique, 
qui a impliqué l'utilisation de trois techniques d'analyse: chromatographie d'affinité à 
haute pression (HPALC), dichroïsme circulaire (CD) et biosenseur optique. L'utilisation 
de ces techniques en synergie a permis d’obtenir une vue claire et complète des 
processus de bioreconnaissance étudiés. 
En particulier, nous avons analysé la liaison des nouvelles entités chimiques à une 
des protéines les plus abondantes du sérum, la sérum albumine humaine (HSA). Cette 
protéine joue un rôle fondamental dans le transport des médicaments, des metabolites 
et des facteurs endogènes, permettant de expliquer la distribution des médicaments 
dans l’organisme humaine. À travers ces techniques il a été possible d'obtenir un 
ranking de tous les composés analysés selon leur liaison avec la protéine, en 
permettant d'identifier facilement les composants avec les caractéristiques 
pharmacocinétiques les plus favorables; de plus, avec l'utilisation de markers 
spécifiques nous avons effectué des études de déplacement, pour identifier les sites 
avec haute affinité sur la protéine. 
La liaison de nouvelles entités chimiques aux protéins plasmatiques des 
différentes espèces animales a été étudié, en particulier HSA et RSA (sérum albumine 
de rat). En effet, l'utilisation de modèles animaux dans les expériences de distribution 
réalisées in vivo représente un point critique des études pharmacocinétiques. Avec ce 
travail, il a été possible de montrer comment les petites différences dans la chaîne 
d’acides aminés de ces deux protéines peuvent conduire à des différences 
significatives dans leur structure tridimensionnelle qui se repércuteront, donc, sur leur 
capacité de liaison et sur leur stéréosélectivité. Obtenir ces informations dans les 
phases précoces d’étude du médicament permettrait une meilleure comparaison entre 
les données obtenues par des expériences in vitro et les données obtenues avec les 
expériences sur l’animale, en facilitant ainsi la suivante extrapolation de ces données 
pour les humains. 
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Enfin, la liaison d'une série de potentiels anticancéreux nouvellement synthétisé 
avec leur target biologique (récepteur des androgènes) a été analysé en utilisant une 
biosenseur optique. Cette technique permet la détermination des constantes d'affinité 
(KD) des complexes analysés et des constantes cinétiques qui guident ces processus 
(kon et koff), en obtenant ainsi une caractérisation complète et détaillée du processus de 
bioreconnaissance étudié. 
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